Investigating Oligosaccharyltransferases Of N-Linked Glycosylation Using Escherichia Coli. by Guarino, Cassandra
  
 
INVESTIGATING OLIGOSACCHARYLTRANSFERASES OF N-LINKED 
GLYCOSYLATION USING ESCHERICHIA COLI 
 
 
 
 
 
 
 
 
A Dissertation 
Presented to the Faculty of the Graduate School 
of Cornell University 
In Partial Fulfillment of the Requirements for the Degree of 
Doctor of Philosophy 
 
 
 
 
 
 
by 
Cassandra M B Guarino 
January 2013
  
 
 
 
 
 
 
 
 
 
 
 
© 2013 Cassandra M B Guarino
  
INVESTIGATING OLIGOSACCHARYLTRANSFERASES OF N-LINKED 
GLYCOSYLATION USING ESCHERICHIA COLI 
 
Cassandra M B Guarino, Ph. D. 
Cornell University 2013 
 
Escherichia coli is a powerful tool for elucidating many of the basic principles 
of biology.  As a protein production host, E. coli can produce exogenous protein to 
upwards of 20% of the total cellular protein content.  While E. coli is used to produce 
a wide variety of proteins for research and therapeutic purposes, this organism is 
limited in its capability to perform various post-translational modifications required 
for the proper function of most mammalian proteins.  One such modification is N-
linked glycosylation, the transfer of an oligosaccharide onto an asparagine residue 
within an acceptor peptide sequence.  N-linked glycosylation can alter the solubility of 
a protein, enhance its effector function, and increase the serum half-life of therapeutic 
proteins.  In recent years, researchers have reconstituted the N-linked glycosylation 
pathway from a distantly related gram-negative pathogen, Campylobacter jejuni, in 
non-pathogenic E. coli.  While engineered strains of E. coli are now capable of N-
linked glycosylation, the type of glycan transferred, the acceptor protein sequence 
modified, and the efficiency of protein modification remain limiting factors in these 
recombinant systems.  To address these limitations, this work focused on 
understanding and improving the oligosaccharyltransferase (OST), the central enzyme 
of the N-linked glycosylation pathway.  First, selection tools were designed to isolate 
 E. coli with enhanced glycosylation capabilities. One of these tools, the glycophage 
display system, was utilized to select for OSTs with altered acceptor site specificity.  
Next, we performed a functional analysis of twenty-three different bacterial OSTs. 
Harnessing the functional diversity in naturally occurring bacterial OSTs combined 
with structure-guided mutations yielded several interesting OSTs with unique acceptor 
site specificities not previously reported. Finally, to further simplify the model 
framework of glycosylation, we designed an in vitro prokaryotic-based cell-free 
system to efficiently synthesize glycoproteins. E. coli has proven to be a useful tool 
for developing a more thorough understanding of N-linked glycosylation, and 
continued research in the field of bacterial glycosylation will undoubtedly lead to new 
and important discoveries with significant impact on the biopharmaceutical industry.   
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CHAPTER 1 
INTRODUCTION 
 
 
Background 
 
 The term ‘protein’ was first coined in 1838 by Jöns Jacob Berzelius, one of the 
founders of modern chemistry, to describe one class of the constituents of living things 
and to express the fundamental significance of certain substances in nutrition1,2.  Today, 
many laymen still think of ‘protein’ as simply a substance of nutrition, but proteins are so 
much more than merely something we have to eat to survive.  Proteins are miraculous 
nano-machines that perform various tasks, from catalysis of chemical reactions to 
structural recognition.  Certainly, protein is an essential component of the diets of all 
animals, but the primary reason for this necessary class of molecules is to obtain the 
amino acid building blocks required for creating novel proteins in the host’s body. 
 Recombinant DNA technology has allowed for closer investigation into protein 
structure and function.  Through the use of molecular cloning techniques, foreign DNA 
can be introduced into an organism, and with the appropriate genetic material to code for 
replication and transcription, non-native and engineered proteins can be produced in a 
myriad of organisms.  The first publication describing the recombinant DNA process for 
creating plasmids which could be replicated in Escherichia coli was published in 19733.  
That work, led by Herbert W. Boyer and Stanley N. Cohen, produced one of the first 
major patents in biotechnology4.  Nearly a decade after the initial proof of concept, 
human insulin became the first commercial protein produced by recombinant DNA 
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technology to be approved for use as a therapeutic in humans5.  This version of insulin, 
known as Humulin®, and also referred to as biosynthetic human insulin (BHI), is 
produced using a fermentation process in E. coli6. 
E. coli is an excellent host for recombinant protein production.  As of 2009, 
approximately 30% of all proteins produced for the biopharmaceutical market were made 
in E. coli 7.  E. coli remains an exceptionally popular and predominantly utilized 
bacterium for the production of recombinant proteins due to: (i) thorough 
characterization, both genetic and physiologic, (ii) well-established fermentation 
methodologies, (iii) rapid growth on inexpensive substrates, (iv) ease of modification 
through a broad range of simple molecular techniques, and most notably, (v) the capacity 
to accumulate foreign proteins to greater than 20% of the total cellular protein content8,9.  
While E. coli continues to prove itself to be remarkably useful for recombinant protein 
production, there are several drawbacks to this particular production host.  The primary 
drawbacks have been the inability to produce proteins composed of multiple subunits or 
requiring substantial post-translational modifications, necessitating the use of more 
complex hosts such as yeast or mammalian cells10.  Recent advancements in E. coli 
protein expression techniques have led to the ability to produce multiple-subunit 
molecules in E. coli, such as full-length immunoglobulin G molecules (IgGs)11,12.  For 
full effector function, however, IgGs also require the post-translational modification 
known as N-linked glycoslation13. 
The focus of this thesis is on utilizing E. coli to better understand the process of 
N-linked glycosylation, with a primary focus on the oligosaccharyltransferase (OST).  
The OST is an enzyme that catalyzes the transfer of the glycan from a lipid carrier in the 
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membrane to the asparagine residue of a nascent peptide containing an N-linked 
glycosylation consensus sequence.  For decades, E. coli has been utilized to elucidate 
many of the basic principles of biology, including the genetic code14, gene regulation15, 
recombinant DNA technology3, and protein production and secretion16.  Because E. coli 
does not contain native N-linked glycosylation machinery and yet can be engineered to 
perform this post-translational modification17, it is an excellent host for the study of N-
linked glycosylation. 
 
 
Protein glycosylation in bacteria 
 
Glycoproteins are ubiquitous in nature, and their existence has been known for 
over a century18.  Protein glycosylation is a post-translational modification that involves 
the covalent linkage of a sugar molecule to a protein.  There are three main types of 
protein glycosylation events that are known to occur: (i) N-linked glycosylation of an 
aspargine residue, (ii) O-linked glycosylation of a serine or threonine residue, and (iii) 
glycosylphosphatidyl inositol derivitization of the carboxy-terminal carboxyl group19.  It 
has been shown that N-linked glycosylation has profound effects on protein structure and 
function19,20, and this type of glycosylation is the focus of this thesis. 
 N-linked glycosylation is necessary for the viability and development of 
eukaryotic organisms21.  In eukaryotes, N-linked glycosylation involves the co-
translational transfer of a pre-assembled tetradecasaccharide, Glc3Man9GlcNAc2-, from a 
dolichol pyrophosphate lipid carrier to the asparagine side chain of a nascent protein 
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within the consensus sequence, N-X-S/T, where X can be any amino acid except 
proline22.  Recently, it has been shown that the core of this glycan, Man3GlcNAc-, can be 
produced in engineered E. coli23.  In eukaryotes, the initial glycan transfer occurs in the 
endoplasmic reticulum (ER), where the protein-bound carbohydrate can be trimmed and 
shuttled to the Golgi apparatus, at which point a variety of modifications take place, 
yielding heterogeneous glycoproteins19.  For many years, the process of N-linked 
glycosylation was thought to be restricted to eukaryotes, never occurring in bacteria; 
however, it is now clear that we should ‘never say never again’24, as systems for N-linked 
glycosylation have been discovered in all domains of life25–27. 
 The first evidence for protein glycosylation in non-eukaryotic cells was 
documented in archaea.  Halobacterium salinarium were found to have glycosylated 
envelope proteins (e.g. surface layer proteins) based on a periodate-Schiff reagent 
reaction with proteins in an SDS-PAGE gel, which is an indication of carbohydrate 
presence.  Covalent linkage of the carbohydrates to surface layer proteins was confirmed 
via tryptic and pronase digestion, suggesting the existence of both O- and N-linked 
glyans28.  
It was first suggested that bacteria may also be capable of N-linked protein 
glycosylation when the surface antigens of Borrelia burgdorferia, a helical shaped 
bacterium known as a spirochete and recognized as the causative agent of Lymes 
disease29, were found to include carbohydrates30.  It was later shown that these 
carbohydrates were N-linked to the surface lipoproteins OspA and OspB based on 
deglysoylation by PNGase F31.  PNGaseF is known to specifically hydrolyze N-linked 
glycans at the β–aspartylglycosylamine bond, yielding ammonia, aspartate, and an 
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oligosaccharide with di-N-acetyl-chitobiose at the reducing end32.   However, this data 
was recently refuted, suggesting that the glycoproteins in those experiments were 
contaminants from the growth media components33. 
 A general method for protein glycosylation in bacteria was discovered in 1999, 
when a genetic locus from Campylobacter jejuni 81-176 was shown to be involved in the 
glycosylation of multiple proteins34.  A few years later, it was determined that the locus 
responsible for general protein glycosylation in C. jejuni contains a protein (PglB) that is 
homologous to STT3, an essential component of the OST complex responsible for 
catalyzing N-linked glycan transfer in eukaryotic cells.  This group further showed that 
the C. jejuni glycosylation locus could be functionally transferred to E. coli cells, giving 
these latter bacteria the ability to perform N-linked glycosylation.  This was significant as 
E. coli normally lack a native N-linked glycosylation pathway17.  Together, these studies 
provided the first conclusive evidence for the existence of N-linked glycosylation in the 
bacterial domain. 
While not necessary for cell survival, the N-linked glycosylation machinery found 
in C. jejuni is essential for full competence of this pathogen35.  Specifically, in the 
absence of the general protein glycosylation machinery, C. jejuni 81-176 has a reduced 
ability to adhere to intestinal cells and to colonize the intestinal tracts of mice36.  
Additionally, mutation of the pglH gene, which is responsible for the addition of the third 
GlcNAc residue of the C. jejuni glycan37, causes C. jejuni to become deficient in its 
ability to adhere to and subsequently invade human epithelial cells in vitro38.  
 Since the discovery that C. jejuni is capable of performing N-linked glycosylation, 
similar systems have been identified in numerous other mucosal pathogens39.  The 
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primary similarity between the eukaryotic and bacterial N-linked glycosylation systems is 
the formation of a β-glycosylamide linkage by en-block transfer of a glycan from a lipid 
carrier in the membrane onto an asparagine amino acid within a specific consensus 
sequence22.  Figure 1.1 depicts the overall similarities between these two systems.  While 
there are many similarities, the glycan that is transferred, the lipid carrier upon which the 
glycan is assembled, and the consensus sequence that is recognized by the OST are 
different.  In eukaryotes, the tetradecasaccharide Glc3Man9GlcNAc2- is preferentially 
recognized by the OST40, while in bacteria, a variety of different oligosaccharides can be 
recognized and transferred by the OST23,41.  Dolichol pyrophosphate and undecaprenyl 
pyrophosphate (UndPP) are the lipid carriers upon which the glycan is assembled in 
eukaryotes and bacteria, respectively.  The eukaryotic consensus sequence is generally 
accepted to be N-X-S/T, and in bacteria, specifically in C. jejuni, this sequence is 
extended to D/E-X1-N-X2-S/T, where X can be any amino acid besides proline42.    
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Figure 1.1. Eukaryotic vs. bacterial N-linked glycosylation. Comparison of N-linked 
glycosylation in prokaryotes (right) and eukaryotes (left). In both systems, several 
glycosyltransferases synthesize the glycan by sequential addition of nucleotide-activated sugars 
on a lipid carrier on the cytoplasmic face of the inner membrane. Once assembled, a flippase 
transfers the LLOs across the membrane where the OST catalyzes the transfer to Asn residues of 
periplasmic or ER substrate proteins. PglB is a single-subunit, integral membrane protein that is 
homologous to the catalytic subunit of the eukaryotic OST STT3 (note that PglB and STT3 
complex are not drawn to scale). Whereas eukaryotes and archaea use an N-X-S/T acceptor 
sequence (where X is any amino acid but Pro), PglB requires an extended motif that includes an 
Asp or Glu residue in the -2 position (D/E-X-1-N- X+1-S/T, where X-1 and X+1 can be any 
amino acid except Pro). PglB can transfer sugars post-translationally to locally flexible structures 
in folded proteins. It remains to be determined whether PglB can transfer sugars co-translationally 
like eukaryotes. This figure was published43 and is re-used here with permission. 
 
The protein glycosylation operon from C. jejuni contains all the genes necessary 
to (i) build the C. jejuni heptasaccharide: GalNAc-1,4-GalNAc-1,4-(Glc1,3)-GalNAc-
1,4-GalNAc-1,3-Bac-44, where bacillosamine (Bac), 2,4-diacetamido-2,4,6-
trideoxyglucopyranose, is a monosaccharide unique to bacteria45, (ii) flip the glycan from 
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the cytoplasmic face to the periplasmic face of the inner membrane, and (iii) transfer the 
glycan onto an acceptor motif.  In vitro assembly of the heptasaccharide using 
overexpressed, purified glycosyltransferases has led to the determination of the precise 
function of these enzymes46,47. Figure 1.2 shows a representation of the function of each 
of the enzymes in the C. jejuni pgl operon; not included in this figure are WlaA, a 
hypothetical protein of unknown function, WlaJ, a putative integral membrane protein of 
unknown function, GalE, an UDP-glucose-4-epimerase, which catalyzes the 
interconversion of UDP-galactose and UDP-glucose48, and PglG, which does not play a 
role in glycan biosynthesis or transfer37,49.  Native E. coli proteins can complement 
portions of the C. jejuni N-linked glycosylation pathway.  For example, PglK, the C. 
jejuni flippase responsible for flipping the assembled glycan from the cytoplasmic face to 
the periplasmic face of the inner membrane, can be complemented by the native E. coli 
Wzx enzyme50.  The wzx gene is thought to encode a flippase that participates in 
lipopolysaccharide (LPS) biosynthesis, specifically transferring UndPP-linked O-antigen 
units across the inner membrane51.  Additionally, O-antigens, which compete for the 
UndPP lipid carrier, can be transferred in place of the C. jejuni glycan when the 
concentration of O-antigens on the inner membrane is increased41,52. Fortunately, for 
glycoprotein engineering purposes, O-antigen biosynthesis is not required for cell 
viability, as is demonstrated by the ability of cells to survive without rfe (also known as 
wecA), the gene responsible for the first step of O-antigen biosynthesis53.   
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Oligosaccharyltransferases 
 
 The OST complex from Saccharomyces cerevisiae is composed of nine subunits: 
Wbp1, Swp1, Stt3, Ost1, Ost2, Ost3, Ost4, Ost5, and Ost6, where the first five are 
essential for the viability of cells and the last four are required for maximal OST 
activity40.  Ost1, Swp1, Wbp1 and Ost2 are homologous to the mammalian OST subunits 
ribophorin I, ribophorin II, Ost48 and DAD1 respectively.  Furthermore, homologues of 
Stt3 (Stt3A and Stt3B), and Ost3/Ost6 (N33 and IAP), and Ost4 are expressed in 
mammalian cells and assemble into multimeric complexes with the Ost1, Swp1, Wbp1 
and Ost2 homologues to form OST complexes similar to those found in yeast54.  Stt3 has 
been determined to be the catalytic subunit of the mammalian OST complex based on 
highly selective cross-linking to nascent polypeptide chains55.  In particular, the five-
Figure'1.2.'Enzymes'in'the'C.#jejuni#pgl#operon.'!This!schematic!shows!the!function!of!each!of!the!enzymes!in!the!C.#jejuni#pgl#operon.!!!
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residue sequence, WWDYG, is believed to be the catalytic motif of the Stt3 subunit 
active site56.  However, the Stt3 subunit alone is not capable of catalyzing glycan 
transfer57. 
 A single subunit enzyme is ideal for bacterial expression and is the type of OST 
investigated in this thesis.  Homologues of the yeast and mammalian OST have been 
identified that contain the WWDYG motif but do not form a multi-protein complex for 
function.  For example, the OST from C. jejuni, PglB, is the only component necessary 
for glycan transfer58.  Additionally, an Stt3 homolog from the archaean Pyrococcus 
furiosus is believed to function as a single subunit59.  Recently, a handful of eukaryotic 
OSTs, derived from protozoans, have also been identified that can function independent 
of a multi-protein complex40,60,61.  Although these protozoan Stt3 homologs are capable 
of replacing the entire OST complex in yeast, it has been proposed that in the absence of 
the complex, substrate specificity is diminished60.  Diminished substrate specificity could 
lead to heterogeneous glycoprotein production, which is problematic when producing 
proteins for use as therapeutics and/or vaccines. 
 In both eukaryotes and bacteria, the peptide substrate for glycosylation must be 
translocated from the compartment in which it is translated (cytoplasm) to the 
compartment in which it is glycosylated (endoplasmic reticulum and periplasm, 
respectively).  Several lines of evidence indicate that N-linked glycosylation is associated 
with the translocon 62,63.  It has been shown through chemical cross-linking studies and a 
split-ubiquitin yeast-two-hybrid system that the components of the OST complex of yeast 
interact with components of the Sec translocon64.  The co-translational Sec translocon in 
yeast is a heterotrimeric complex known as the Sec61 complex, composed of Sec61p, 
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Sss1p, and Sbh1p, and a homologous translocation pathway exists in bacteria, known as 
SecYEG65,66.  In addition to the SecYEG translocon, translocation of proteins to the 
bacterial periplasm can occur via the twin-arginine translocation pathway (Tat), which 
transfers fully folded proteins and protein complexes containing an appropriate signal 
peptide out of the cytoplasm67,68.  While interaction between the SecYEG translocon and 
the bacterial OST have yet to be determined, it is clear that this interaction is not 
necessary for glycosylation, as fully folded proteins transported to the periplasm via the 
Tat translocation pathway are still able to be glycosylated69,70. 
 Recently, the crystal structure of the Campylobacter lari OST in complex with a 
bound peptide substrate in the active site was solved71.  This was the first full-length OST 
structure to be elucidated, including both the membrane-integrated domain and the 
membrane extrinsic domain.  The previously solved structure of the C-terminal soluble 
domain of C. jejuni PglB72 aligns well with the C. lari structure. However, the exclusion 
of the transmembrane helices in the C. jejuni structure caused a significant portion of the 
active site domain to be absent.  With a three-dimensional structure now available to 
work from, structure-guided rational design and directed evolution can be implemented 
for the isolation of mutations that alter or improve bacterial OST function73.  
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Significance 
 
Glycoproteins in vaccine development 
 
 The surfaces of pathogenic bacteria are covered with a variety of unique 
carbohydrate structures.  These carbohydrates are excellent candidates for vaccine 
development.  It is well-established that carbohydrates alone will not produce protective 
immunity against a pathogen, however, conjugation of these glycan structures to proteins 
can offer varying degrees of immunity74. 
The earliest example of a carbohydrate-bound protein used for immunization is 
described by Avery and Goebel75, who demonstrated the ability to produce glycan-
specific antibodies in rabbits by vaccinating animals with specific carbohydrates 
covalently bound to proteins in vitro.  Since that time, it has been clearly demonstrated 
that proteins conjugated to bacterial polysaccharide can offer immunity to infection.  One 
noteworthy example is the Haemophilus influenza type b conjugate vaccine, which was 
first introduced in the late 1980s76, with variations later approved77.  H. influenza is now 
considered eradicated in some areas78.  A comprehensive review on glycoconjugate 
vaccines was published in 2005 that provides further examples of glycoconjugate 
vaccines currently in use or in various stages of clinical trials79. 
Early glycoconjugate vaccines were produced by chemical linkage of the 
carbohydrate to a protein.  The ability to attach specific carbohydrates to proteins in vivo 
opened a new pathway for glycoprotein vaccine production, which led to the formation of 
GlycoVaxyn, a privately held Swiss biopharmaceutical company founded in 2004.  The 
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GlycoVaxyn technology is based on the observation that the C. jejuni OST is 
promiscuous.  That is, in addition to transferring N-glycans, PglB is also capable of 
modifying target proteins with a variety of bacterial O-antigens when their concentration 
in the inner membrane is increased by preventing their export from the inner-membrane 
to the outer surface of E. coli41.  The ability to produce glycoprotein conjugate vaccine 
candidates in vivo has since been demonstrated.  For example, AcrA from C. jejuni or 
PAE from Pseudomonas aeruginosa can be glycosylated in E. coli cells co-expressing 
the Shigella dysenteriae type 1 O-antigen and PglB from C. jejuni80.  More recently, it 
was found that by expressing a glycoprotein along with the C. jejuni OST directly in 
Yersinia enterocolitica O9 cells, a less pathogenic relative of the Brucella abortus 
pathogen, glycoproteins could be produced that elucidated immune reactivity to Brucella 
in mice, though protection was not achieved81.    
In addition to attachment of glycans to soluble proteins, outer membrane vesicles 
(OMVs) containing glycoproteins could be utilized as vaccines.  OMVs are non-
replicating membrane-encapsulated structures released from some gram-negative 
bacteria.  They are composed of outer membrane lipids, outer membrane proteins, LPS, 
and contain periplasmic components in the lumen82.  The sugars, proteins, and lipids 
found in OMVs are foreign to the mammalian system and are immunogenic83, allowing 
them to be an effective adjuvant for vaccine delivery.  Additionally, OMVs are 
internalized by mammalian cells84, which could aid in vaccine delivery throughout the 
body.  We have demonstrated that a variety of outer-membrane proteins can be 
glycosylated, as described in Chapter 2.  Furthermore, our group has shown that it is 
possible for some outer membrane glycoproteins to be localized to OMVs69.  
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 There are several challenges associated with the production of glycoprotein and 
OMV vaccines produced from E. coli.  One of these challenges is related to the OST, C. 
jejuni PglB, which has been found to only transfer oligosaccharides that contain an 
acetamido group at the C-2 carbon of the reducing end sugar52.  Since many 
immunologically relevant bacterial carbohydrates do not contain the required acetamido 
group at the reducing end, efforts to discover and/or design OSTs with novel function is 
necessary85.  The methods described in Chapter 2 of this thesis could be extended to 
select for OSTs that more efficiently transfer specific O-antigens, or other bacterial 
glycans, by replacing the C. jejuni pgl locus with a locus expressing the genes required to 
build the specific bacterial glycan of interest. 
 
 
Therapeutic glycoproteins 
 
The biopharmaceutical sector is a rapidly growing segment of the pharmaceutical 
industry.  Biopharmaceuticals, which are predominantly recombinant protein 
therapeutics, but also encompass nucleic acid-based products and engineered cell or 
tissue-based products, were estimated to have a global market value of $70-80 billion in 
201086.  However the sales of general biologics in that same year, which are primarily 
recombinant protein therapeutics and antibodies, are documented to have exceeded $100 
billion, where therapeutic monoclonal antibodies accounted for approximately 48% of 
those sales 87.  Currently, approximately 70% of the human therapeutic proteins on the 
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market are N-linked glycoproteins88.  As mentioned previously, monoclonal antibodies, 
specifically IgGs, require N-linked glycosylation for full effector function13.  
 In addition to antibodies, a variety of other therapeutic proteins require N-linked 
glycosylation in order to achieve optimal therapeutic activity.  One therapeutic 
glycoprotein of interest is erythropoietin, which functions to regulate red blood cell 
production and is used to treat anemia caused by chronic kidney disease or 
chemotherapy.  Erythropoietin has also been shown to have nonhaematological effects 
including the prevention of ischaemia-induced tissue damage89.  The complete absence of 
sugar residues on erythropoietin, as produced from non-engineered E. coli, results in a 
1000-fold decrease in in-vivo activity90.  Engineering the protein with two addition N-
linked glycosylation sites, for a total of four, yields the derivative Darbepoetin alfa which 
exhibits a three-fold increase in serum half-life and increased in-vivo activity91.  Another 
therapeutic glycoprotein engineered for improved efficacy is tissue plasminogen activator 
(t-PA), a serine protease used in the treatment of acute myocardial infarction92.  A third 
generation t-PA, Tenecteplase (TNKase), was engineered such that the glycan was 
moved from residue 117 to residue 103, leading to eight-fold slower clearance from 
serum and 200-fold greater resistance to plasminogen-activator inhibition while 
maintaining function93.  
 The significance of N-linked glycosylation in therapeutic proteins is clear, and the 
functional transfer of the N-linked glycosylation machinery from C. jejuni to E. coli has 
opened the door to engineering the cellular machinery of E. coli to produce therapeutic 
glycoproteins.  Significant strides have been made in the engineering of E. coli towards 
this goal, including the biosynthesis of the core Man3GlcNAc2- structure of the 
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eukaryotic glycan in E. coli, which was transferred by the C. jejuni OST, albeit with low 
efficiency23.  While the engineered Man3GlcNAc2- glycan was transferred to target 
proteins by the C. jejuni OST, this required the more specific bacterial acceptor sequence 
(D/E-X1-N-X2-S/T).  Hence, any acceptor sequences in eukaryotic glycoproteins that lack 
a negatively charged residue two amino acids upstream of the glycosylation consensus 
sequence are not currently recognized in the engineered bacterial system.   
Chapters 2 and 3 of this thesis describe efforts that have been made to attempt to 
overcome the limitations of the bacterial OST, including the development of a variety of 
selection tools to select for improved function, and a functional analysis of OST 
homologues from other bacterial species.  Chapter 4 presents a novel method for 
characterizing OSTs in vitro, and Chapter 5 details proposed future work that will allow 
us to draw closer to the goal of creating ‘humanized’ and other engineered glycoproteins 
in E. coli. 
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CHAPTER 2 
DEVELOPMENT OF A SELECTION TOOL FOR  
N-LINKED GLYCOSYLATION IN ESCHERICHIA COLI 
 !
Introduction 
  
 The addition of an oligosaccharide to a protein sequence can have significant and 
dramatic impacts on the properties of the protein, including, but not limited to, improved 
stability, altered susceptibility to proteolysis, enhanced folding and solubility, varied 
pharmacokinetic properties, and enhanced effector function13,94–97.  The introduction of 
N-linked protein glycosylation machinery into E. coli has opened the door to engineering 
therapeutic proteins and novel vaccine technology in this prolific protein production host.  
While it has been clearly demonstrated that E. coli can successfully glycosylate proteins 
with a variety of different oligosaccharides, both in our lab and by others23,41,69, the 
efficiency of glycosylation, the specific site that is glycosylated, and the specificity of the 
glycan that is transferred are all areas that need to be improved in order to take full 
advantage of E. coli as a glycoprotein production host.   
In order to make improvements to the glycosylation machinery in E. coli, we set-
forth to develop a selection tool which could be utilized to isolate variant glyco-
engineered E. coli displaying enhanced properties of glycosylation.   To this end, it was 
necessary to develop a tool that allows for the maintenance of a link between the 
genotype and the phenotype of a specific protein sequence glycosylated with a specific 
sugar moiety.  Our primary goal here was to design a tool that links genetic alteration of 
the glycosylation machinery, specifically, the OST, to the effects on glycosylation.   
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In our initial attempts, a surface display system was developed in which 
glycosylated proteins are displayed on the surface of E. coli.  It was discovered that E. 
coli expressing the C. jejuni glycosylation machinery non-specifically displayed the C. 
jejuni oligosaccharide on their surface, and this challenge was overcome through 
genomic alterations. It was shown that glycoproteins could be displayed and detected on 
the surface of E. coli, however initial attempts to isolate glycosylation competent cells 
from those not capable of glycosylation were of limited success.  Alterations to this 
system are currently being investigated, and the next steps underway to successfully 
utilize this surface display system are presented. 
An additional attempt to design a glycosylation selection tool in E. coli involved 
the design of a glycosylation site located adjacent to a proteolytic cleavage site. Our 
hypothesis was that close proximity of a glycan to the cleavage site could interfere with 
the enzyme recognition and inhibit proteolytic cleavage. While the specific construct 
designed and presented here did not support our hypothesis, additional constructs that 
could prove successful are elucidated.    
Finally, we established a phage display system, with which we could select for 
glycoproteins containing the previously established acceptor sequence from a pool of 
proteins with mutated acceptor sites98.  We went on to utilize the phage display system to 
select for functional alterations of the OST.  The results of this selection are presented.   
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Results and Discussion 
 
Outer membrane glycoprotein display 
 
 Our hypothesis was that if we could display glycosylated proteins on the surface 
of E. coli, we would be able to separate E. coli that are capable of glycosylation from 
those that were not glycosylation-competent.  Furthermore, we anticipated that cells 
carrying genetic alterations leading to more efficient glycosylation would display more 
glycan on their surface and could potentially be selected from a pool of cells with less 
efficient glycosylation.  
The C. jejuni N-linked heptasaccharide binds to soybean agglutinin (SBA), a 
lectin that recognizes terminal GalNAc residues17.  SBA is a large tetrameric protein, 
~120kDa, that should not be capable of penetrating the E. coli outer membrane.  
Fluorescently labeled SBA-AlexaFluor 488 (SBA-488) was used to probe cells for the 
presence of cell surface C. jejuni glycans.  Initial experiments led to the discovery that E. 
coli expressing the C. jejuni pgl locus displayed SBA-binding glycan on their surface in 
the presence or absence of glycosylated protein.  This led to the hypothesis that the C. 
jejuni glycan was hijacking the native LPS biogenesis machinery of E. coli. To test this 
hypothesis, E. coli K-12 BW23113 with either the rfaL gene or the rfaC gene deleted 
were chosen as candidate hosts99.  The rfaL gene, or waaL, encodes the O-antigen ligase 
that catalyzes the transfer of an O-antigen to the LPS core100.  The rfaC gene, or waaC, 
encodes the LPS heptosyl transferase I that is responsible for the transfer of the first 
heptose residue onto the inner core of the LPS101.  Both rfaC and rfaL knock-out cell 
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lines showed a dramatic decrease in fluorescence labeling compared to the parental 
strain, with the rfaC knock-out having the lowest level of outer membrane display of the 
C. jejuni glycan (Figure 2.1).  This data supports our hypothesis that the C. jejuni glycan 
can hijack the LPS machinery of E. coli.  Following Western blot verification of 
glycosylation of a native C jejuni substrate (data not shown), BW23113ΔrfaC was chosen 
as the cell line for surface display. 
 
 
Figure 2.1. Selection of cell line for surface display. (a.) Schematic of the function of rfaC and 
rfaL. (b.) Mean fluorescence of cells expressing the C. jejuni pgl locus following labeling with 
SBA-488.  The results are the average of four independent samples. 
 
Prior to this work, only soluble periplasmic proteins had been glycosylated in E. 
coli cells carrying the C. jejuni pgl locus.  Therefore, it was necessary to first investigate 
whether outer membrane proteins could be N-glycosylated.  The first protein we 
investigated was C. jejuni OmpH1 (CjaA), a native C. jejuni surface lipoprotein, 
containing one glycosylation consensus sequence, (137DSNIS141)102,103. When produced in 
cells co-expressing the C. jejuni pgl locus, glycosylated CjaA could be detected by 
a. b. 
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Western blot, and in cells where the OST was mutated to prevent glycosylation (pglmut), 
no glycosylated CjaA was detected (Figure 2.2a). A significant increase in fluorescence 
was detected for BW23113ΔrfaC cells co-expressing the functional C. jejuni pgl locus 
and CjaA compared to those lacking a functional OST (Figure 2.2b). Introducing a 
D137A point mutation, which removes the negatively charged residue at the -2 position 
of the glycosylation consensus motif, making it not recognized by the OST, caused a loss 
of fluorescence signal in glycosylation-competent BW23113ΔrfaC cells, as expected; 
additionally, a C20A point mutation downstream of the signal peptide required for 
lipoprotein processing and localization104 led to a similar loss of fluorescence signal 
(Figure 2.2b). 
Following verification of the presence of glycosylated CjaA on the surface of 
cells, attempts were made to isolate SBA-488-labeled bacteria. For this experiment, we 
generated artificial libraries, consisting of 1:100 mixtures of cells expressing glycosylated 
CjaA to cells expressing aglycosylated CjaA.  Following two rounds of screening by 
fluorescence activated cell sorting (FACS), no enrichment of glycosylation competent 
cells was achieved, leading to the hypothesis that the number of glycans on the surface of 
BW23113ΔrfaC cells was insufficient for efficiently separating cells.  
In an attempt to increase the number of SBA-488-accessible glycans on the 
surface, a strategy previously utilized in the DeLisa lab research group to put multiple 
glycans onto maltose binding protein (MBP) was employed69.  An engineered GlycTag 
(GT) acceptor sequence was inserted into the second extracellular loop of the β-barrel 
outer membrane protein OmpX from E. coli, as described previously for outer membrane 
display of peptide sequences105.  The resulting OmpX-GT construct contained four 
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potential glycosylation sites in tandem.  Glycosylated OmpX could be detected by 
Western blot only in cells co-expressing a functional C.jejuni pgl locus (Figure 2.2a). As 
seen above with CjaA, significant increase in fluorescence was detected in 
BW23113ΔrfaC cells co-expressing OmpX-GT and the functional C. jejuni pgl locus 
compared to those lacking a functional OST (Figure 2.2b).  Outer membrane localization 
of glycosylated OmpX-GT in BW23113ΔrfaC cells expressing the C. jejuni pgl locus 
was further verified with fluorescence microscopy (Figure 2.2c). 
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Figure 2.2 Expression of outer membrane glycoproteins. (a.) Western blot analysis of OmpX-
GT or CjaA expression in cells co-expressing pACYCpgl (+) or pACYCpglmut (-).  (b.) Flow 
cytometric analysis of BW23113ΔrfaC cells expressing OmpX-GT, CjaAD137A, CjaAC20A or CjaA 
and co-expressing pACYCpgl (+) or pACYCpglmut (-). Cells were labeled with SBA-488.  The 
data presented is the average of three independent replicates, with error bars representing the 
standard error of the mean. (c.) Light and fluorescence microscopy of BW23113ΔrfaC cells 
expressing OmpX-GT and co-expressing pACYCpgl (+) or pACYCpglmut (-). This figure was 
published69 and is re-used here with permission. 
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Similar to the test sorts of CjaA, OmpX-GT was produced from both 
glycosylation competent cells and from cells lacking a functional OST, and a 1:100 
mixture was used as a ‘false library’ for determining the sortability of this system.  This 
time, instead of labeling with SBA-488 and sorting on the FACS Calibur, the cells were 
mixed with SBA-agarose beads.  The beads were then washed, and the bound cells were 
recovered and tested for the presence of funtional OST.  To our surpise, there was again 
no significant improvement in the ratio of glycosylation competent to non-glycosylation 
competent cells. 
Currently, this selection tool is being re-visited by a post-doc in the DeLisa lab 
research group, Dr. Anne Ollis.  In an effort to further increase the number of accessable 
glycans on proteins on the surface of E. coli, the FimA protein has been targeted.  The 
fimA gene encodes the subunit of type 1 fimbriae in E. coli106.  Fimbriae are long fibrous 
structures which protrude from the surface of bacteria and aid in the attachment to 
external surfaces for colonization.  On the order of 500 fimbriae can be found on the 
surface of one E. coli cell, each containing approximately 1000 copies of the FimA 
subunit107.  FimA fusions have been  previously been utilized to succesfully display 
heterologous peptides on the surface of E.coli108.  The fimA gene was cloned from the 
genome of E. coli W3110, and a single DQNAT glycosylation motif was inserted 
between residues S27 and V28 of mature FimA, yielding FimA-GT.  This site was 
chosen based on succesful peptide display positions identified in the previously published 
study.  Cells co-expressing FimA-GT along with the C. jejuni pgl locus showed enhanced 
binding to hR6, an antibody raised against the C. jejuni glycan109, in comparison to cells 
lacking a functional OST (Figure 2.3b). Mixtures of glycosylation-competent cells 
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expressing FimA-GT with cells expressing FimA-GT but with an inactive glycosyaltion 
locus were prepared and selected on a plate coated with the hR6 antibody.  Following 
recovery, cells were detected from a dilution as low as 1:1000, where, based on OD600, 
approximately 100,000 cells were incubated in each well. Verification of glycosylation 
competency of the recovered cells was inconclusive, as the pgl locus could not be 
detected following cell re-growth. Studies to determine the level of FimA glycoprotein 
display and its utility in library screening are ongoing.  
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 The ability to display and detect glycoproteins on the surface of bacteria has been 
confirmed, but more research is necessary to improve the ability to isolate glycosylation 
competent cells from a background of cells that are not capable of glycosylation in order 
to utilize this system as a selection tool for N-linked glycosylation in E. coli. Improving 
the number of glycans displayed on the surface of E. coli by selecting a protein that is 
Figure'2.3.'E.#coli#expressing'glycosylated'FimA'bind'to'glycan=specific'hR6'
antibody.'(a.!@!c.)'Spot!plate!results!from!cells!recovered!following!binding!to!hR6.!!(a.)!BW23113!pgl+!vs!BW23113ΔrfaC!pgl+.!(b.)!CLM24!pgl+!pFimA@GT!vs!CLM24!pglmut.pFimA@GT!(c.)!Dilutions!of!CLM24!pgl+!pFimA@GT:CLM24!pglmut!pFimA@GT;!dilutions!were!based!on!normalized!OD.!(d.)!Artistic!rendition!of!fimbriaeted!E.#
coli.!(e.)!Model!of!glycosylated!FimA!
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displayed in significantly higher quantity on the surface may prove to be the solution that 
allows this system to be successfully utilized. 
 
 
Glycan-protected protease cleavage 
 
In general, the addition of an oligosaccharide confers a level of protease 
resistance to a protein; this can be due to the (i) increased rigidity of a protein caused by 
the orientation of the hydrophilic carbohydrates on the protein surface, or (ii) steric 
protection of susceptible protease cleavage sites by the large oligosaccharide structure110. 
Indeed, it has been shown that alterations to glycosylation can impact observed 
proteolytic cleavage patterns111–113. 
 Since it is clear that glycosylation of a protein sequence can decrease proteolysis, 
we hypothesized that a glycosylation site located within or near a specific protease 
cleavage site could inhibit the cleavage site recognition and subsequent proteolytic 
degradation, as depicted in Figure 2.4.  Therefore, we setout to create a fusion protein 
construct that was protected from proteolytic cleavage when glycosylated, and fully 
hydrolyzed when aglycosylated. In order to maintain the genotype-phenotype linkage 
necessary to develop this technology into a selection tool for N-linked glycosylation in E. 
coli, the fusion protein was designed as an integral membrane protein. 
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Figure 2.4 Schematic of glycan-protected protease cleavage. Our hypothesis is that, in the 
presence of a glycan, a protease cleavage site can be protected from degradation, as depicted here. 
 
Many proteases cleave non-specifically or have broad substrate specificity.  There 
are, however, a number of commercially available proteases with strict substrate 
specificities.  The protease we chose to test first was tobacco etch virus (TEV) protease 
(Invitrogen; Ac-TEV). TEV protease recognizes the peptide sequence ENLYFQ(G/S) 
and cleaves the protein following the glutamine residue114.  To test our hypothesis that a 
glycan could protect this site, a hybrid TEV protease cleavage site/bacterial N-linked 
glycosylation site, DQNATENLYFQG, was engineered into a target protein.  The 
protease cleavage site served as a linker between MBP and g3p of M13 bacteriophage.  
The g3p protein is transiently inserted into the inner membrane prior to incorporation into 
phage115, allowing for display of proteins on the inner membrane of E. coli.  Displayed 
proteins can be selected after spheroplasting of the bacterial cells, a process which results 
in disruption of the outer membrane and hydrolysis of the peptidoglycan layers, leaving 
an intact cytoplasmic membrane enclosing the cytoplasm. Indeed, a technology termed 
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APEx has been described in which combinatorial antibody libraries fused to g3p were 
selected for enhanced ligand binding by isolating spheroplasts with high affinity for the 
ligand116.  MBP was chosen as the fusion partner because it is a thoroughly characterized 
soluble periplasmic protein117, and it can be easily selected for based on binding to an 
amylose resin (NEB). 
The first step towards our goal of using glycan-protected protease cleavage as a 
selection tool for N-linked glycosylation was to verify that glycosylation of the site 
prevents proteolytic degradation.  To investigate this, whole cell lysates were prepared 
from an equivalent number of E. coli cells co-expressing the MBP-GT-TEV-g3p protein 
and the C. jejuni pgl locus with or without a functional OST. Lysates were treated with 
Ac-TEV protease at 30°C for 30min, and the reactions, including controls lacking 
protease, were resolved on SDS-PAGE, and proteins were visualized by Western blot 
(Figure 2.5).  Unfortunately, results with this construct indicated that the fusion protein 
was hydrolyzed by the protease regardless of the glycosylation state. 
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It is clear from Figure 2.5 that the glycosylated fusion protein was degraded in the 
presence of TEV protease, indicating that this cleavage site was not protected by the 
presence of the C. jejuni glycan.  While the specific construct described above did not 
demonstrate glycan-protected protease cleavage as hoped, our hypothesis that a 
glycosylation site located within or near a specific protease cleavage site could inhibit 
recognition and prevent degradation should not be rejected, as there are a variety of other 
constructs that hold promise and should be investigated.  Three additional possibilities for 
construct design are described here. 
Bovine enterokinase (Sigma), a highly specific serine protease, can be used to 
cleave an N-terminal FLAG epitope-tag from fusion proteins; the specific recognition site 
of bovine enterokinase is XDDDDKX-PX, where X is any amino acid and X-P is any 
amino acid besides proline, and cleavage occurs following the lysine residue118. Based on 
Figure'2.5.'TEV'protease'cleavage'site'is'not'protected'by'adjacent'glycan.'(a.)Western!blot!detection!of!whole!cell!lysates!from!glycosylation!competent!E.#coli!expressing!MBP@GT@TEV@g3p.#Whole!cell!lysate!with!and!without!TEV!protease!digestion!are!depicted.!The!blot!is!probed!with!hR6!for!detection!of!glycan.!(b.)!Schematic!of!protease!degradation.!(i)!MBP@GT@TEV@g3p.!(ii)!MBP@GT. 
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the structural sensitivity, as noted by the inability of the protease to recognize the 
sequence when the residue following the cleavage site is a proline, this protease could 
potentially be inhibited by a glycan positioned on an asparagine in the X-P position, as in 
the sequence XDDDDKNAT. 
Another protease worth investigating is Factor Xa protease (NEB), which cleaves 
following the arginine in the specific sequence I(D/E)GRX, where X can be an amino 
acid besides proline and arginine119.  We have noted that, in some cases, it is possible for 
bacterial OSTs to glycosylate an asparagine that has a negatively charged residue in the -
3 position120. Again, the structural specificity of this protease is revealed by the inability 
to tolerate a proline following the cleavage site, indicating that the presence of a glycan at 
that position could impact protease recognition of the site.  A site such as IDGRNAT 
could hypothetically be glycosylated by a bacterial OST, potentially inhibiting cleavage 
by Factor Xa protease. 
Finally, and possibly the most promising protease, thrombin (GE Healthcare), is a 
serine protease that recognizes the peptide sequence LVPRGS and cleaves between the 
arginine and glycine121.  It has been shown that this protease can tolerate a S/T in place of 
the valine in its recognition sequence122.  Additionally, this protease does not tolerate 
hydrophilic residues near the N-terminus of the recognition sequence123,124. Therefore, it 
is likely that a hydrophilic glycan preceding this cleavage site could interrupt recognition 
by this protease.  The extended sequence LTPRGVRL is an efficiently recognized 
sequence for thrombin125.  A sequence such as DQNLTPRGVRL would likely be 
recognized in the absence of glycosylation, whereas glycosylation of the asparagine could 
potentially protect this site from proteolysis. 
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Phage display of glycoproteins 
 
 Phage display of proteins and peptides has proven to be a powerful tool for 
isolating protein subunits with increased binding affinity for a particular substrate126.  The 
technique for displaying phage particles with associated fusion peptides was first 
described in 1985127.  Since that time, phage display has been primarily utilized for the 
selection of improved binding of proteins to a ligand128–131, and has also been used to 
select for increased protein stability132,133, and increased enzymatic function131,133. 
Additionally, phage display has been utilized to elucidate the substrate specificity for a 
variety of proteases125,134,135.  While significantly less common, phage display can also be 
utilized to investigate complex enzymatic pathways.  One specific example is the use of 
M13 phage to provide the genotype-phenotype linkage necessary to elucidate mutations 
in DsbC, a native E. coli disulfide bond isomerase, that led to enhanced substrate folding 
in the periplasm of E. coli136. 
Here, we hypothesized that phage expressing proteins glycosylated with the C. 
jejuni glycan should be selected based on their increased affinity to a glycan-specific 
lectin.  As previously mentioned, the C. jejuni glycan is known to have an affinity for 
SBA.  Working in conjunction with Dr. Eda Çelik, a post-doc in the DeLisa lab research 
group, we developed a genetic screen for glycosylation in E. coli based on the display of 
N-linked glycoproteins on the tail-region of M13 phage particles98.  The basis of this 
system is a genetic fusion between g3p, the minor coat protein of M13 phage, and a target 
protein containing an optimized glycosylation consensus sequence tag for N-linked 
glycosylation69.  The fusion protein contains a signal peptide which directs its secretion to 
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the periplasm through the SecYEG translocon137, where glycosylation can take-place if a 
functional pgl locus is co-expressed.  Recovery of phage particles containing 
glycosylated protein on their surface was demonstrated following lectin affinity 
chromatography.  Recovered phage are used to re-infect cells in order to establish the 
necessary genotype-phenotype linkage through replication of the phagemid. In initial 
studies, the phagemid carried the N-linked glycoprotein, but was later re-designed to also 
carry the OST, and could be further engineered to carry any of the components of the 
glycosylation machinery.   
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In proof-of-concept studies98, we demonstrated the ability of the phage display 
system to be utilized in the selection of glycosylation consensus sequences that can be 
recognized by the OST. The optimal acceptor sequence for the OST of C. jejuni is 
DQNAT138. Utilizing this information, a C-terminal fusion of the DQNAT glycosylation 
tag was made to MBP.  This construct was then cloned in-frame with g3p into pBAD24, 
a plasmid which carries the M13 phage origin of replication and thus serves as the 
phagemid for these experiments139. Western blot analysis verified that this construct was 
produced in E. coli and was glycosylated only when (i) the functional C. jejuni locus was 
present, and (ii) the DQNAT acceptor site was present98, as verified by immunoblot with 
anti-MBP and hR6. 
In order to demonstrate that this system was useful for the selection of 
glycosylated phage, TG1 E. coli cells expressing the C. jejuni pgl locus and a phagemid 
containing either MBP-GT-g3p or MBP-g3p were infected with VCSM13 helper phage 
Glycosylated!phage 
Figure'2.6.'Schematic'of'glycophage'production.!!Glycosylated!phage!particles!are!produced!from!TG1ΔwaaL!cells!co@expressing!the!C.#jejuni#pgl#locus!and!a!phagemid!encoding!the!glycoprotein,!MBP@GT@g3p.!!Production!of!phage!particles!is!induced!by!infection!with!helper!phage.!
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to induce the production of modified phage particles.  Phage titers were quantified by 
infection of fresh TG1 cells with the phage preparations, followed by selection on 
ampicillin (Amp), the antibiotic resistance conferred by the phagemid, to determine 
colony forming units (CFU).  Western blots of isolated phage particles confirmed the 
presence of glycosylated protein only in the case where the DQNAT site and functional 
C. jejuni pgl locus were present98. A mixing experiment was used to determine whether 
glycosylated phage particles could be isolated by binding to the SBA lectin. A 1:1 
mixture of glycosylated to aglycosylated phage particles were incubated with the 
agarose-bound SBA, washed several times with PBS and PBS containing 30mM 
galactose, and finally eluted with PBS supplemented with 300mM galactose, which 
competitively binds SBA140, allowing for the release of the bound phage particles.  
Utilizing a PCR-based assay, it was verified that 22/28 of the phagemids recovered 
encoded for the MBP-GT-g3p construct98. 
While the ratio of DQNAT-containing phagemid particles was significantly 
greater than the starting 1:1 mixture, it should be noted that the overall number of phage 
eluted following this initial sort was significantly below the theoretical maximum 
recovery expected if the actual starting mixture were 1:1.  This low recovery can be 
explained by the fact that (i) glycosylation in E. coli has been shown to be relatively 
inefficient141, and (ii) lectins exhibit weak binding for their carbohydrate ligands, 
generally requiring multivalency to achieve high avidity142. Furthermore, it was later 
found that we could select up to 5/22 phagemid constructs encoding MBP-GT-g3p from a 
1:106 mixture following just a single sort98. These data led us to the conclusion that this 
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system could be utilized for the selection of libraries of enzymes in the N-linked 
glycosylation pathway expressed in E. coli. 
 To demonstrate the ability of this selection tool to select libraries of enzymes, we 
first investigated whether a library of the acceptor sequences could be sorted.  It has been 
previously shown that the bacterial OST, specifically C. jejuni PglB, requires a 
negatively charged residue two base-pairs upstream of the asparagine that is 
glycosylated143.  Therefore, a library was created by random mutagenesis of the aspartic 
acid residue in the DQNAT acceptor site, leading to the production of phagemids 
expressing an XQNAT glycosylation site, of which only DQNAT and EQNAT sites 
should be glycosylated.  A library of approximately 1x109 phage was sorted as described 
above, and following a single round of sorting, 30/47 of the sequenced clones contained a 
negatively charge aspartic acid residue at the -2 position.  While no clones were selected 
containing a glutamic acid residue, we have previously observed that the glycosylation of 
acceptor sequences is significantly greater in the presence of an aspartic acid residue as 
compared to a glutamic acid residue (data not shown). 
 In conjunction with our publication98, another report describing the use of phage 
display to select for improved glycosylation phenotypes in E. coli was published144.  This 
further supported our hypothesis that glycophage could be useful for selection of 
improved function of enzymes in the C. jejuni pgl locus, or any other N-linked 
glycosylation locus that could be expressed in E. coli. 
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Sorting an OST library with the phage display system 
 
 Following verification that the phage display system could be utilized to select 
phage particles displaying glycosylated proteins on their surface98, we proceeded to sort a 
library of C. jejuni PglB in an attempt to select a variant that no longer required a 
negatively charged residue in the -2 position.  Based on the recent crystal structure of C. 
lari PglB, a homolog of C. jejuni PglB, it was determined that the R331 residue of the 
OST potentially forms a salt bridge with the negatively charged residue in the -2 position 
of the acceptor peptide to be glycosylated71.  In C. jejuni PglB, aligned to C. lari PglB, 
this residue is adjacent to an additional positively charged residue.  Therefore, a library 
was created using NNK random primers, where 327RR328 of C. jejuni PglB was randomly 
mutated. The resulting library was called the R2 library. 
 Prior to sorting of this library, several modifications were made to the glycophage 
selection system.  First, based on the results of Dürr et al.144, it was determined that 
utilizing an antibody against the glycan, specifically hR6, could more efficiently select 
for glycosylated phage due to the increased binding affinity of antibodies as compared to 
lectins.  Secondly, it was noted that a truncated version of g3p (tg3p) could lead to more 
efficient protein display on phage145.  Finally, we were interested in selecting for 
glycosylation sequences that did not contain a negatively charged residue at the -2 
position of the asparagine that gets glycosylated.  Therefore, a phagemid was designed 
containing MBP-2xAQNAT-tg3p along with the C. jejuni PglB R2 library.  The MBP-
2xAQNAT-tg3p and PglB library members were expressed bicistronically, each with 
their own ribosome-binding site (RBS).  
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 Following two rounds of sorting over hR6, bound through biotin to streptavidin 
beads, ten clones were selected at random and characterized.  It was found that one of 
these ten constructs produced phage particles with significantly increased glycosylation, 
however the size of the glycosylated protein was found to be significantly smaller than 
full-length MBP-2xAQNAT-tg3p fusion protein (Figure 2.7a). The mutation in this 
selected OST is 327ER328.  We next determined whether this selected OST had increased 
recognition for glycosylation sites lacking a negatively charged residue at the -2 position.  
This was tested by sub-cloning the gene encoding PglB327ER328 into a plasmid with 
AcrA’0x’, a version of the AcrA glycoprotein containing four glycosylation consensus 
sequences in which each is mutated to have an alanine at the -2 position.  Unfortunately, 
no improvement in glycosylation over wild-type (wt) C. jejuni PglB was observed 
(Figure 2.7c).   
The observed glycosylated product from the selected phagemid was smaller than 
the expected fusion protein, so we wanted to determine whether this altered phenotype 
was dependent on the selected OST.  To test this, wt C. jejuni PglB was sub-cloned into 
the selected phagemid in place of C. jejuni PglB327ER328.  It was found that wt C. jejuni 
PglB was also capable of glycosylating the glycoprotein expressed from this construct 
(Figure 2.7d).  These results, however, are not fully conclusive, as it is possible that the 
original phagemid containing C. jejuni PglB327ER328 was not eliminated during the 
cloning process. 
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Figure'2.7.'Investigating'OST'selection.'(a.)!Western!blot!of!phage!particles!produced!from!glycosylation!competent!E.#coli!co@expressing!a!phagemid!with!(+)MBP@GT@tg3p!and!wt!C.#jejuni#PglB,!or!(ER)!MBP@2xAQNAT@tg3p!bicistronic!with!the!R2!library!member,'C.#jejuni#PglB!327ER328.!(b.)!Schematic!of!C@terminally!truncated!MBP@2xAQNAT@g3P!in!the!membrane!and!integrated!into!phage!particles.!(c.)!Western!blot!of!periplasmic!fraction!from!glycosylation!competent!CLM24!cells!expressing!AcrA’0x’!and!wt!C.#jejuni#PglB!(RR)!or#C.#jejuni#PglB!327ER328.!(d.)!Western!blot!of!phage!particles!produced!from!glycosylation!competent!E.#coli!expressing!wt!C.#jejuni#PglB!bicistronic!with!(+)!MBP@GT@tg3p!and,!(@)!MBP@2xAQNAT@tg3p!and!(RR)!MBP@2xAQNAT@tg3p!from!the!phagemid!containing#C.#jejuni#PglB!327ER328.!(i)!MBP@2xAQNAT@tg3p.!(ii)!truncated!product.!!
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Upon closer analysis, it was found that five random point mutations were present 
in the selected phagemid, four of these point mutations resided in the coding sequence for 
MBP.  It is likely that the original phagemid construction contained a mixture of 
plasmids, some of which harbored these mutations.  Interestingly, NCBI orf finder 
(http://www.ncbi.nlm.nih.gov/projects/gorf/) predicts that the mutated gene encodes a C-
terminal truncation mutant, tMBP-2xAQNAT-tg3p. The size of this predicted truncation 
mutant is approximately 25kDa smaller than the full-length fusion, which is the size of 
the glycosylated product we observed  (Figure 2.7, ii). As mentioned, the DQNAT 
sequence is the optimal acceptor sequence, and the mutation of the first residue in the 
sequence to an alanine may not be sufficient to fully disrupt the interaction of this peptide 
in the active site of the OST.  In addition, the residue preceding the first AQNAT 
sequence in this construct is a negatively charged glutamic acid, which has been seen to 
relax the specificity of the OST when present in this location120. To confirm this theory, 
the novel coding region could be cloned freshly into a new vector and glycosylation by 
wt C. jejuni PglB and C. jejuni PglB327ER328 could be analyzed. 
It should be noted that the library sorted here was small, with only 322 possible 
unique OSTs, and that there is not necessarily a C. jejuni PglB R2 library member that is 
capable of efficiently glycosylating the AQNAT glycosylation sites tested here.  
However, the specific mutation isolated from these library sorts correlates with the 
observed structure-guided mutations described in Chapter 3, where it was shown that the 
R331E mutation of C. lari PglB leads to enhanced glycosylation of scFVR4-AQNAT 
over that of wt C. lari PglB.  Finally, while the results presented in Figure 2.7d indicate 
that wt C. jejuni PglB can also glycosylate the mutated acceptor sequence selected from 
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these library sorts, these results are not fully conclusive. Further analysis is necessary to 
determine whether C. jejuni PglB327ER328 offers improved glycosylation of the AQNAT 
acceptor site over wt C. jejuni PglB. 
 
 
 
 
Materials and Methods 
 
Bacterial Strains and Plasmids 
 
DH5α cells were used for plasmid cloning, replication and storage; CLM24 cells 
were used for general glycoprotein production; BW23113ΔrfaC cells were used for 
surface display of glycoproteins. TG1 E. coli were utilized for phage production and 
grown in M9 medium for selection of the presence of the F’ plasmid, followed by growth 
and induction in 2xTY medium; all other E. coli cells were grown in Luria-Bertani 
medium. Cells were grown at 37°C and induced at 30°C.  Induction of glycoprotein and 
phage production proceeded overnight. Culture medium was supplemented with 50mM 
glucose during the growth phase and with 30mM arabinose during the induction phase.  
Antibiotics were supplemented into the culture medium where appropriate at the 
following concentrations: 100 µg/mL Amp, 20 µg/mL chloramphenicol (Cm), and 50 
µg/mL kanamycin (Kan). 
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Table 2.1. Strains and Plasmids used in these studies 
Strain or plasmid Relevant genotype or description Reference or source 
E. coli 
       DH5α F– Φ80lacZΔM15 Δ(lacZYA-argF) U169 
recA1 endA1 hsdR17 (rK–, mK+) phoA 
supE44 λ– thi-1 gyrA96 relA1 
Laboratory stock 
     CLM24 W3110 (IN(rrnD-rrnE)1 rph-1)  ΔwaaL  Feldman et al. 
     TG1ΔwaaL  
supE hsdΔ5 thi Δ(lac-proAB) F' [traD36 
proAB lacI lacZΔM15] ΔwaaL Laboratory stock 
     BW23113ΔrfaC K-12 BW25113 ΔwaaC (rfaC) Laboratory stock99 
Plasmids     
     pBAD24 Cloning vector, aribinose-inducible, Ampr Guzman et al. 
     pPglΔB 
 
pMW07 containing the C. jejuni pgl locus 
without pglB 
 
Glycobia 
      
     pACYCpgl  
pACYC184-based plasmid encoding the C. 
jejuni protein glycosylation locus cluster 
Linton et al. 
     
     pACYCpgl mut 
 
pACYC184-based plasmid encoding the C. 
jejuni protein glycosylation locus cluster, 
were pglB has been inactivated 
Linton et al. 
      
 
Biopanning of cells 
 FACS sorting was performed on a Becton Dickinson FACSCalibur.  Following 
induction of outer membrane glycoprotein, cell dilutions were prepared as described and 
were probed with SBA-488 (Invitrogen) in PBS for 45 minutes in the dark, and run on 
the FACSCalibur.  Cells with relative fluorescence over 102 were collected in PBS and 
concentrated by filtration; the filter paper was placed on a LB-agar plate containing the 
appropriate antibiotics.  The glycosylation phenotype was confirmed by sequencing of 
pglB.  In most cases, a PCR product for pglB was not obtained.  
 Panning of cells over hR6 was performed by binding of biotinylated hR6 antibody 
to a streptavidin plate (Pierce), following the manufacturers instructions.  Cells were 
incubated on the plate for 1hr at 25°C.  The wells were then washed 12 times with 200µL 
of PBS.  Cells bound to the plate were recovered following a 1hr incubation at 37°C in 
! 43!
SOC supplemented with Amp and Cm.  Recovered cells were spotted onto LB-agar 
plates supplemented with Amp and Cm.  
 
Phage purification 
 Phage particles were produced from E. coli TG1 ΔwaaL carrying a phagemid 
expressing a g3p fusion protein and pACYCpgl, pACYCpglmut or pPglΔB.  20mL 
cultures of cells were infected with VCSM13 helper phage at OD600 0.5-0.6, and 
incubated at 37°C for 30min without shaking.  Infected cells were then pelleted and 
resuspended in 100mL 2xTY medium supplemented with Cm, Amp, Kan and arabinose 
for 16hr at 30°C.  Phage were purified using PEG/NaCl precipitation, and helper phage 
titers were determined as described elsewhere146. 
  
Biopanning of phage 
SBA panning: Phage particles, 109 CFU in PBS, were incubated for 1hr at 25°C 
with 1mL of agarose-bound SBA (Vector Laboratories).  Following incubation, agarose-
bound SBA was pelleted at 100g for 5min and washed with 10mL of PBST (PBS with 
0.1% Tween20) four times, followed by three washes with 10mL of 30mM galactose in 
PBST.  Glycosylated phage particles were eluted in three steps using 1 mL of 300mM 
galactose in PBS.  Eluted phage particles were then used to infect E. coli TG1 cells.  
DNA was recovered from infected cells for verification of genotype. 
 hR6 panning: The hR6 antibody was conjugated to biotin, allowing for the 
conjugation to streptavidin beads (Invitrogen), and panning of phage was carried-out as 
previously described144. 
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Phagemid library construction 
 The C. jejuni PglB R2 library was constructed by overlap extension PCR of the C. 
jejuni pglB gene using the internal NNK primer 5’-
AGAAGATTATGTGGTAACTTGGNNKNNKTATGGTTATCCTGTGCGTTATTATAG-3’ and its 
reverse complement.  The forward primer for pglB contained an RBS at the 5’ end, 
allowing the PCR product to be cloned into pBAD24 between XbaI and SbfI, following 
the MBP-2xAQNAT-g3p sequence. 
 
 
Western blot analysis 
 
Expression and glycosylation of g3p fusion constructs, AcrA, and outer 
membrane proteins were analyzed by immunoblot following SDS–PAGE of phage 
particles, periplasmic fractions and whole cell lysates, as indicated. Immunodetection was 
performed with monoclonal anti-His antibody (Abcam, ab1187), polyclonal anti-OmpX 
antibody105, monoclonal anti-MBP antibody (NEB, E8038), and polyclonal anti-glycan 
serum hR6 (S. Amber and M. Aebi, personal communication), as indicated.  
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Conclusions  
 
 The surface display system is a promising tool for selection of glycosylation-
competent E. coli.  Research is currently underway to enhance the number of 
glycosylated proteins on the surface of E. coli in order to be able to more efficiently 
separate glycosylation competent cells from those that are not capable of or less efficient 
in the process of glycosylation.  We discovered that the C. jejuni glycan can be displayed 
on the surface of wt E. coli in the absence of glycosylation, and we were able to prevent 
export of glycan to the surface by genomic removal of either one of two enzymes in the 
LPS pathway. 
 The C. jejuni glycan located upstream of the protease recognition sequence was 
not sufficient to prevent digestion with TEV protease.  Although this specific construct 
did not produce the desired results, this does not rule out the possibility of creating a 
selection tool using this strategy. Currently, several other constructs are in development 
in an attempt to create a protease cleavage site that can be protected from protease 
recognition by the presence of the C. jejuni glycan.   
 Phage display of glycoproteins has been shown to be a promising method for 
selecting improvements to the glycosylation phenotype98,144.  Extending this selection 
tool for the selection of variant OSTs brought to light some of the challenges of high-
throughput selection technology – ‘you get what you select for’.  We discovered that, 
while we were able to select for improved glycosylation of proteins displayed on phage, 
these improvements were not necessarily associated only with alterations to the OST.  
Re-designing this system to stabilize the glycosylation machinery and acceptor protein, 
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through genome integration of the glycosylation machinery and/or the MBP-GT-g3p 
fusion, for example, and including only the target enzyme on the phagemid, could lead to 
significant improvements of this selection tool.     
 Overall, this work has provided insight into the process of N-linked glycosylation 
in E. coli and has laid the foundation for future selections where improvements to the 
glycosylation machinery are isolated using glycoengineered E. coli.  
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CHAPTER 3 
FUNCTIONAL ANALYSIS OF BACTERIAL N-LINKED 
OLIGOSACCHARYLTRANSFERASES 
 
 
Introduction 
 
 
N-linked glycosylation is a common post-translational modification found in all 
eukaryotic cells, which is required for cell viability147. In the last decade, it has been 
clearly established that this modification is present in all domains of life26,27,34.  While it 
is clear that N-linked glycosylation is an important aspect of most living things, there is 
still a significant amount of information left to be uncovered in order to successfully 
employ this process for therapeutic protein and vaccine development.  Bacterial N-linked 
glycosylation is not required for cell viability, and E. coli does not naturally have the 
ability to produce N-linked glycoproteins.  Therefore, the E. coli host is an excellent 
candidate for the study of N-linked glycosylation.  The central enzyme of all N-linked 
glycosylation pathways is the OST, which catalyzes the transfer of an oligosaccharide 
onto a protein.   
 OSTs responsible for N-linked glycosylation are membrane-spanning enzymes 
that catalyze the transfer of an oligosaccharide from a lipid carrier in the membrane onto 
a protein within a target consensus sequence.  In eukaryotic cells, this sequence is 
typically N-X-S/T, where X can be any amino acid besides proline.  In bacteria, this 
sequence is not sufficient for glycosylation148.  Glycosylation of native C. jejuni proteins 
occurs only when a negatively charged residue is located two residues upstream of the 
asparagine that gets glycosylated. Hence, the bacterial consensus sequence has been 
defined as D/E-X1-N-X2-S/T, where X1 and X2 can again be any amino acid beside 
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proline143.  It was later discovered that the optimal acceptor sequence for the C. jejuni 
OST is DQNAT138.  Currently, the most thoroughly characterized bacterial OSTs are 
from C. jejuni and its close relative C. lari. 
PglB from C. jejuni is a single subunit protein containing 713 amino acids with 11 
predicted N-terminal transmembrane helices, followed by a soluble C-terminal domain 
oriented towards the periplasm.  This later domain, comprises approximately one third of 
the protein149.  The C. jejuni OST is responsible for the glycosylation of more than 65 
periplasmic and membrane proteins with various functions26,39. A crystal structure of the 
soluble domain of C. jejuni PglB was recently solved72, which revealed a new structural 
motif within the predicted active site. Shortly thereafter, the crystal structure of full-
length C. lari PglB was solved71. This structure contained a divalent metal ion cofactor, 
which had previously been suggested to be necessary for OST function150, and an 
acceptor peptide containing the optimized glycosylation consensus sequence bound in the 
proposed active site.  The structure also confirmed that C. lari PglB has 13 
transmembrane helices, where the predicted periplasmic region between the second and 
third helix149, crosses the membrane.  This additional membrane spanning region places 
the predicted lipid carrier recognition domain on the cytoplasmic face of the membrane71.  
The inclusion of the acceptor peptide in the crystal structure of C. lari PglB revealed 
previously undiscovered interactions between the enzyme and its protein substrate.  The 
five-residue sequence, WWDYG, was previously proposed to be the catalytic motif of the 
OST active site56,151, and indeed these residues were found to be in close proximity to the 
acceptor peptide in the C. lari OST.  All functional OSTs investigated to date contain a 
similar sequence, however some OST homologues contain slight variations in this 
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sequence, with W/N/F replacing Y72.  The glycan substrate was not included in the C. lari 
PglB structure, however a non-structured region of external loop 5 was indicated as the 
likely interaction domain for glycan recognition71. 
It is evident that the glycan recognition regions of bacterial OSTs have relaxed 
specificity, as many of the bacterial OSTs studied to date demonstrate promiscuity in 
glycan recognition.  The ability of the C. jejuni PglB to transfer O-antigens onto proteins 
at an appropriately situated asparagine residue has been previously demonstrated41,73.  
The OST from Desulfovibrio desulfuricans can similarly transfer O-antigens onto 
protein, albeit at a lower efficiency than C. jejuni PglB. Besides O-antigen promiscuity, 
the D. desulfuricans OST and one of the two Helicobacter pullorum OSTs can efficiently 
transfer the C. jejuni glycan152,153.  Likewise, the C. jejuni OST can transfer the 
pentasaccharide N-glycan from H. pullorum153.  Therefore, we hypothesized that other 
bacterial OSTs would likely exhibit similar promiscuity and be capable of transferring the 
C. jejuni glycan.  Further, we hypothesized that some of the bacterial OSTs studied might 
have altered acceptor site specificity 
 In these studies, we analyze the ability of numerous bacterial OSTs (listed in 
Figure 3.1) to transfer the C. jejuni glycan onto proteins containing both native and 
modified glycosylation consensus sequences.  Not surprisingly, we found that the OSTs 
with the greatest homology to C. jejuni PglB efficiently transferred the C. jejuni glycan 
onto native as well as engineered C. jejuni glycoproteins.  A preliminary investigation 
into the unexpected variations in site specificity of the W. succinogenes OST is presented, 
as well as an unexpected relaxed acceptor site specificity observed for C. jejuni PglB.   
Several of the bacterial OSTs were observed to transfer the C. jejuni glycan to an altered 
! 50!
acceptor site that lacked the negatively charged residue at the -2 position.  This result 
suggested some bacteria, such as Desulfovibrio strains, have evolved distinct acceptor 
site specificity. Finally, we performed structure-guided mutagenesis to engineer an active 
site variant of C. lari PglB exhibiting altered acceptor site specificity.  
 
 
 
 
 
 
 
 
 
 
 
Nucleotide Substitutions (x100)
0
191.5
20406080100120140160180
Ccoli
Cjejuni
Cupsaliensis
Clari
Hpullorum_2
Hydrogenivirga
Nitratiruptor
Sulfurovum
Chominis
Sdenitrificans
Cfetus
Cconcisus_2
Cgracilis_2
Cconcisus
Cgracilis
Wsuccinogenes
Ddesufuricans
Dvulgaris
Dgigas
Figure'3.1'Phylogenic'tree'of'OSTs'investigated'in'this'study.!The!tree!was!created!following!alignment!of!OST!sequences!by!the!ClustalW!method!using!MegAlign!from!DNASTAR!Lasergene!8.#
! 51!
Results and Discussion 
 
Native C. jejuni glycoproteins 
 
 
 Twenty-three different PglB homologues from seventeen unique bacterial species 
and two closely related subspecies were tested for their ability to transfer the native C. 
jejuni glycan onto two model glycoproteins from C. jejuni (Figure 3.2).  The first 
glycoprotein analyzed was AcrA, a native C. jejuni glycoprotein with two native 
glycosylation sites.  Here, we used a version of AcrA called AcrA4x that was engineered 
to contain two additional glycosylation sites by replacing the residues at the -2 positions 
of two naturally occurring NXT sites with aspartic acid: F115D, and T145D 143.   The 
second protein analyzed was Cj0114, a native C. jejuni glycoprotein with four native 
glycosylation sites.  Each glycoprotein was expressed bicistronically from a plasmid that 
also expresses the OST.  A C-terminal 6x-His tag was also added to each glycoprotein for 
ease of detection.  The order of the OSTs in Figure 3.2 is based on predicted phylogenetic 
distance of the OST from C. jejuni PglB.  C. coli encodes the most closely related OST, 
having 80.8% amino acid sequence identity.  Phylogenetic distances are difficult to 
determine with significant accuracy for the more distantly related OSTs, such as those 
from Desulfovibrio bacteria, which have only 13-15% amino acid identity to C. jejuni 
PglB.     
To estimate the efficiency with which the different OSTs transferred the C. jejuni 
N-glycan onto the two C. jejuni substrates tested here, we performed Western blot 
analysis.  Efficiency can be estimated from a blot using anti-His antibodies, where the 
number of bands corresponds to the different glycoforms (eg. a-, mono-, tri-, and tetra-
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glycosylated) and the intensity of the bands corresponds to the relative amount of protein 
at that size.  The C. jejuni oligosaccharide is approximately 1kDa, which allows for 
distinct separation of a-, mono-, di-, tri-, and tetra-glycosylated proteins.  
The OSTs that were most efficient at glycosylating AcrA4x were the OSTs from 
C. jejuni, C. coli, and C. concisus based on the ability of these enzymes to generate 
predominantly fully glycosylated glycoprotein targets (Figure 3.2). Comparatively, the C. 
lari OST, which has been previously shown to be capable of glycosylating a non-
canonical site, 257DANSGT262, for a total of five possible sites in AcrA4x154, proved to be 
less efficient at overall glycosylation under these conditions.  The efficiency of 
glycosylation at this non-canonical site is significantly lower than that of the native sites, 
therefore it is not surprising that is was not detected.  
Previous studies indicate that C. jejuni PglB should be capable of efficiently 
glycosylating all four of the sites in Cj0114153.  In multiple replicates, however, only two 
of those sites were efficiently glycosylated by C. jejuni PglB, with some indication of 
low-level glycosylation of a third site.  The C. coli and C. concisus OSTs were the only 
other OSTs investigated here that show evidence of glycosylating more than one of the 
four sites in Cj0114. Sequencing results confirmed the presence of all four glycosylation 
sites in this construct, hence the lack of tetra-glycosylated Cj0114 was not the result of a 
cloning error.  It should be noted that while these results are at odds with previously 
published data153, they are consistent with our earlier observation that the C. jejuni OST 
is more efficient at glycosylating acceptor sites having an aspartic acid at the -2 position 
versus a glutamic acid at the -2 position (data not shown).  These results are also 
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supported by our glycophage selection results, where the majority of acceptor site 
sequences selected by this system contained an aspartic acid in the -2 position98.   
 
 
The overall expression level of AcrA4x was low when co-expressed with the 
OSTs from both C. upsaliensis and C. hominis, however, the anti-glycan blot verifies that 
these enzymes were still capable of glycosylating this protein.  A possible explanation for 
this observed low expression level is that the expression of these particular OSTs caused 
Figure'3.2'Glycosylation'of'a'native'and'a'modified'C.#jejuni#substrate'by'bacterial'
OSTs.'Western!blot!of!periplasmic!fraction!from!CLM24!cells!co@expressing!pACYCpgl!B::Kan!with!the!indicate!OST!and!either!(a.)!AcrA4x!or!(b)!Cj0114.!The!bacterial!OSTs!are!denoted!as!follows:!1!C.#jejuni;!2!C.#coli;!3!C.#upsaliensis;!4!C.#lari;!5!C.#concisus!;!6!C.#fetus;!7!
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increased stress on the cells, leading to lower overall expression and/or increased 
proteolysis of the AcrA-4x target protein.  
OSTs from two C. fetus subspecies both exhibited the same glycosylation 
patterns.  Specifically, mono- and tri-glycosylated AcrA4x were the prominent 
glycoforms generated by the C. fetus OSTs, indicating that these OSTs may have 
preferential specificity for particular sites in this protein. Along similar lines, both C. 
fetus OSTs glycosylated only one of the four sites in Cj0114, to approximately the same 
efficiency, further indicating a particular sequence preference. 
C. gracilis, C. concisus and H. pullorum all contain a second OST in their 
genomes, OST*, which is more distantly related to C. jejuni PglB, and none of these 
OSTs were capable of glycosylating the native C. jejuni substrates tested here. In 
agreement with these data, the H. pullorum OST* was previously shown to be incapable 
of glycosylating Cj0114, however in those studies, two of the potential sites in Cj0114 
were glycosylated by the H. pullorum OST153.  In these studies, OSTs from both H. 
pullorum subspecies glycosylated only one site in Cj0114, and only the H. pullorum MIT 
subspecies was capable of glycosylating AcrA4x.  
The OST from Sulfurovum sp. did not show evidence of glycosylating AcrA, but 
did glycosylate one site in Cj0114, and the OSTs from Hydrogenivirga sp., Nitratiruptor 
sp, and the Desulfovibrio bacteria did not prove capable of glycosylating either AcrA4x 
or Cj0114 with the C. jejuni oligosaccharide. These data indicate that these OSTs are (i) 
not well expressed in E. coli, (ii) cannot recognize the C. jejuni glycan, or (iii) have 
variation in their glycosylation site specificities. 
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The OST from D. desulfuricans, which is more homologous to eukaryotic and 
archaeal OSTs than the Campylobacter OSTs are, was recently reported to glycosylate 
one of the two native sites in AcrA when recombinantly expressed in E. coli155.  
Specifically, this group found that the site, 271DNNNST276, was glycosylated at N274.  In 
our in vivo experiments, there is no evidence of this site being glycosylated.  The likely 
explanation for this apparent discrepancy is that different expression levels of the OST 
and glycoprotein could have an impact on the enzyme function.  The same cell line and 
glycosylation machinery were used in the D. desulfuricans experiments as were used 
here, but the glycoprotein expression vector and the OST expression vector were 
different, where the glycoprotein was produced from a high-expression pET vector, and 
the OST was expressed from a separate vector, pMLBAD, originally designed for 
optimal expression in Burkhoderia156.  
Collectively, these data support our hypothesis that numerous bacterial OSTs are 
capable of recognizing the C. jejuni glycan and transferring it onto a target protein. One 
important point is that the glycoproteins tested here contained the generally accepted 
bacterial consensus sequence143.   Our goal of identifying bacterial OSTs with variations 
in acceptor site specificity is descried below.  
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Variations in acceptor site-specificity of PglB homologues 
 
A particularly interesting result from the glycosylation of native C. jejuni 
substrates was that of the Wolinella succinogenes OST, where only mono-glycosylated 
AcrA4x was observed. In order to determine which site was being glycosylated, four 
different AcrA’3x’ variants were created.  These mutants each contained one point 
mutation that removed the negatively charged residue from the -2 position of one of the 
acceptor site sequence, D115A (Δ1), D121A (Δ2), D145A (Δ3), or D273A (Δ4). The W. 
succinogenes OST was cloned bicistronically with each of these AcrA’3x’ variants. The 
ability of this OST to glycosylate the different AcrA’3x’ proteins was investigated.  
These experiments revealed that removing the negatively charged residue preceding 
N117 prevented the W. succinogenes OST from glycosylating AcrA’3x’ (Figure 3.3).  
Based on these results, it can be concluded that the W. succinogenes OST has altered site 
specificity. While this OST can glycosylate the asparagine of 115DENAS119, the 
negatively charged residue is required.  The inability to glycosylate the other three 
acceptor sites of AcrA4x indicates that the D/E-X1-N-X2-S/T site alone is not sufficient 
to promote glycosylation of asparagine by this OST.    
!!!
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A subset of the bacterial OSTs were tested for their ability to transfer the C. jejuni 
glycan onto a mutated version of AcrA4x, called AcrA’0x’, for which each of the four 
glycosylation sites were mutated to contain an alanine at the -2 position of the 
glycosylation consensus sequence (Figure 3.4a).  AcrA’0x’ should not be glycosylated by 
C. jejuni PglB given its known acceptor site specificity.  However, we were less certain 
about the C. lari PglB homolog because it was shown that this OST has relaxed site 
specificity compared to the C. jejuni OST.  Specifically, it was shown that the C. lari 
OST glycosylated the 271DNNNST276  site when D271 was mutated to alanine (D271A) 
or when N273 was mutated to glutamate of lysine154.  In our expression system, the C. 
lari OST was not capable of glycosylating AcrA’0x’. Remarkably, however, C. jejuni 
PglB was capable of generating a mono-glycosylated form of AcrA’0x’.     
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Figure'3.3'Analysis'of'the'glycosylation'of'AcrA'by'the'W.#succinogenes#OST!(a.)!Hypothetical!structure!of!AcrA!with!the!four!glycosylation!sites!labeled!in!red,!adapted!from!the!structure!of!MexA20.!(b.)Western!blot!of!periplasmic!fraction!from!CLM24!cells!expressing!W.#succinogenes#OST!along!with!the!C.#jejuni#glycosylation!operon!sans!pglB!and!one!of!five!engineered!AcrA!constucts,!as!indicated!
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Figure 3.4 Analysis of glycosylation of altered acceptor site by C. jejuni PglB. Western blot of 
periplasmic fraction from CLM24 cells co-expressing the C. jejuni pgl locus without PglB and 
(a.) AcrA‘0x’ and the OST indicated, or (b.) AcrA’3x’ with alanine in the -2 position at the 
indicated site and C. jejuni PglB. 
 
To determine which of the four AX1NX2(S/T) sites of AcrA’0x’ was 
glycosylated, C. jejuni PglB was tested for its ability to glycosylate the four different 
AcrA’3x’ constructs described above (Figure 3.4b).  It was found that 271ANNNST276 site 
is glycosylated by C. jejuni PglB, albeit at lower efficiency than for the other three sites, 
as indicated by the lack of signal for the fourth band in the anti-His blot. The arrow in the 
anti-glycan blot of Figure 3.4b denotes the fourth band, where the band above in all four 
lanes is a background band. This allows us to conclude that this fourth site of AcrA is 
indeed glycosylated by C. jejuni PglB in the absence of a negatively charged residue at 
the -2 position.  This is the first report, to our knowledge, that rejects the hypothesis that a 
negatively charged, acidic, residue is strictly required for catalysis of C. jejuni PglB. 
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Our original hypothesis was that some bacterial OSTs would contain natural 
variations in site specificity. To determine if any of the other bacterial OSTs we have 
investigated have relaxed specificity, each OST was tested for its ability to transfer a 
glycan onto scFvR4-AQNAT.  The scFvR4 protein was selected as the glycoprotein 
target because of its highly soluble nature157 and its ability to be glycosylated when 
appended with a GT at its C-terminus43.  The scFvR4-AQNAT construct was cloned into 
pBAD24, and each of the OSTs was cloned into a separate vector, pSF, which introduced 
a FLAG epitope tag to the C-terminus for detection via Western blot.  Our results 
indicated that the C. coli and C. upsaliensis OSTs are capable of transferring a glycan 
onto scFvR4-AQNAT (shown in Figure 3.5 for the C. coli OST).  Comparing the 
sequences of the C. coli and C. upsaliensis OSTs to the C. lari OST, several amino acid 
sequence variations were found in common.  Of particular interest is the P325 residue of 
C. lari; just downstream of this residue is the R331 residue believed to help stabilize the 
acceptor peptide in the active site of the OST (Figure 3.6a).  In both the C. coli and C. 
upsaliensis OSTs there is an arginine aligned to the R331 residue of the C. lari OST, and 
the residue aligned to P325 of the C. lari OST is a leucine.  The rigid nature of proline 
could force the R331 residue into the active site, and a leucine in this position could alter 
the structure enough to explain the relaxed specificity observed here. 
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The most remarkable results presented in Figure 3.5 are those of the OSTs from 
the three Desulfovibrio bacteria.  While none of these OSTs were capable of 
glycosylating native C. jejuni substrates, all three Desulfovibrio OSTs tested glycosylate 
not one, but two sites in scFvR4-AQNAT.  There is only one AQNAT site engineered in 
the construct, so these OSTs are clearly glycosylating some other site.  Upon closer 
investigation of the scFvR4 sequence, it is evident that there are a variety of possible sites 
that could be getting glycosylated.  The two asparagine residues with the highest 
likelihood to be glycosylated by the Desulfovibrio OSTs are 32FSNYS36 and 75RDNAT79, 
both of which contain the standard eukaryotic NX(S/T) motif but lack a negatively 
charged residue at the -2 position.  Site directed mutagenesis combined with mass 
spectrometry is necessary to confirm which of the sites is glycosylated.  As mentioned, 
the Desulfovibrio OSTs are distantly related to the Campylobacter OSTs, and more 
closely related to archaeal and eukaryotic OSTs than are the Campylobacter OSTs.  
1''''2''''3'''''4''''5''''6''''7''''8''''9'''10''11''12''13''14'15'16'17'18'19''20'21''22'23 
α=His 
α=glycan 
Figure'3.5.'Glycosylation'of'a'modified'acceptor'site'by'bacterial'OSTs.'Western!blot!of!periplasmic!fraction!from!CLM24!cells!expressing!pACYCpgl!B::Kan,!scFVR4@AQNAT!from!pBAD24,!and!pBOST!(noted!OST).!The!bacterial!OSTs!are!denoted!as!follows:!1!C.#jejuni;!2!C.#
coli;!3!C.#upsaliensis;!4!C.#lari;!5!C.#concisus!;!6!C.#fetus#fetus;!7!C.#fetus#venerealis;!8!C.#gracilis;!9!
C.#hominis;!10#W.##succinogenes;!11!S.#denitrificans;!12#Sulfurovum#sp!NBC37@1;!13!
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Therefore, it seems logical that the Desulfovibrio OSTs may recognize glycosylation 
consensus sequences that more closely resemble those of the eukaryotes.    
These data further support our hypotheses that (i) most bacterial OSTs exhibit 
broad specificity for the glycan, allowing them to transfer the non-native C. jejuni glycan, 
and (ii) some bacterial OSTs exhibit relaxed acceptor site specificity compared to C. 
jejuni PglB. 
 
 
Structure-guided alteration to site-specificity 
 
The crystal structure of the C. lari OST71 indicated the likely formation of a salt 
bridge between R331 of the OST and the aspartic acid residue at the -2 position of the 
glycosylation acceptor site, with a distance of <4Å between the two residues (Figure 
3.6a). To determine whether this residue, and thus the putative salt bridge, is required for 
glycosylation, we mutated this position in the C. lari OST to a neutral residue (e.g., 
R331G) or a negatively charged residue (R331E). Not surprisingly, mutation of this 
residue to negatively charged residue abolished glycosylation of the four standard 
bacterial acceptor sites in AcrA4x containing a negative residue at the -2 position (Figure 
3.6b).  This result is likely a product of the charge clash introduced by this mutation.  
However, the C. lari PglB mutant carrying a neutral R331G mutation was able to 
glycosylate AcrA4x as efficiently as the wt C. lari OST (Figure 3.6b). 
We next tested whether swapping the charge at the -2 position from a negatively 
charged residue to a positively charge arginine would restore glycosylation in the context 
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of the C. lari R331E OST.  For this experiment, an scFvR4-RQNAT construct was 
created and the C. lari R331E OST mutant was tested for its ability to transfer a glycan to 
this construct (Figure 3.6c).  Unfortunately, the C. lari R331E OST was unable to 
glycosylate scFvR3-RQNAT, indicating that simple swapping of the charged amino acids 
was insufficient to restore glycosylation. Interestingly, the scFVR4-AQNAT construct, 
which was not glycosylated by the wt C. lari OST was successfully glycosylated by the 
C. lari R331E OST (Figure 3.6c).  Thus, the R331E mutation appears to have altered the 
acceptor site specificity of C. lari PglB.  This mutant enzyme has lost the ability to 
glycosylate sites with negatively charged residues at the -2 position (e.g., DFNRS), but it 
has acquired the ability to glycosylate acceptor sites which lack a charged residue in the -
2 position of the acceptor site (e.g., AQNAT) 
Harnessing the functional diversity in naturally occurring bacterial OSTs and 
combining this with structure-guided mutations has yielded several interesting OSTs with 
unique acceptor site specificities not yet reported. 
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Figure 3.6 Mutational analysis of C. lari PglB. (a.) Close-up of the interaction between R331 of 
C. lari PglB (grey) and the aspartic acid in the -2 position of the glycosylation acceptor site 
(green); the dashed line corresponds to a distance of 2.4Å (from the 3RCE structure in the protein 
data bank71). (b.) Western blot of periplasmic fractions from CLM24 cells co-expressing 
pACYCpgl B::Kan, the noted C. lari OST and either (b.) 4xAcrA or (c.) scFvR4-AQNAT or -
RQNAT. 
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Materials and Methods 
 
Bacterial Strains and Plasmids 
 The bacterial strains and plasmids used in the study are listed in Table I. E. coli 
were grown at 37°C overnight in Luria-Bertani broth and protein inductions were carried-
out at 30°C. Amp (100µg/mL), Cm (20µg/mL), and spectinomycin (Sp, 75µg/mL) were 
added to the medium as required for plasmid maintenance. Template DNA for the OSTs 
was obtained from ATCC where available, or provided as a generous gift from the 
laboratory of Bil Clemons of the California Institute of Technology.  
 OSTs were cloned using directional cloning between XbaI and SbfI of pBad24, 
downstream of the acceptor protein sequence in the bicistronic constructs, or following 
the RBS in the pSF plasmid.  The pSF plasmid was constructed by insertion of a 
truncated MBP sequence, preceded by an XbaI cut site and followed by the coding 
sequence for a FLAG-tag, with an SbfI cut site in-between into pSN1843 between NcoI 
and SalI.  The pBS plasmid was constructed for expression of the acceptor protein on a 
third plasmid by combining the spectinomycin resistance cassette and pSC101 ori from 
the pZ expression vectors158, digested with AvrII and AatII with the expression region of 
pBad24, copied with primers pBadAvrIIfor (5’-
AACATACCTAGGATCGATGCATAATGTGCCTGTC-3’), and pBadAatIIrev (5’-
AAGATTGACGTCGATGCCTGGCAGTTTATGG-3’). 
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Table 3.1. Strains and plasmids used in this study 
Strain or plasmid Relevant genotype or description Reference or source 
E. coli 
       DH5α F– Φ80lacZΔM15 Δ(lacZYA-argF) U169 
recA1 endA1 hsdR17 (rK–, mK+) phoA 
supE44 λ– thi-1 gyrA96 relA1 
Laboratory stock 
     CLM24 E. coli W3110 (IN(rrnD-rrnE)1 rph-1) waaL  Feldman et al.
41 
Plasmids     
     pACYCpgl   
     B::kan 
pACYC184-based plasmid encoding the C. 
jejuni protein glycosylation locus cluster, 
where pglB has been replaced with kanr, 
Cmr 
Linton et al.37 
     pBAD24 Cloning vector, aribinose-inducible, Ampr Guzman et al.
139 
     pBS Cloning vector, arabinose-inducible, Spr This study 
     pSF Cloning vector, arabinose-inducible, Ampr This study 
 
 
Introduction of point mutations to AcrA 
 Point mutations were introduced into AcrA using the QuikChange II site directed 
mutagenesis kit (Agilent Technologies Inc., Santa Clara, CA).  Complementary primers 
were designed to mutate the aspartic acid residue to an alanine for each of the four 
glycosylation consensus sequences in AcrA using the primer design software provided 
through the Agilent website.  
 
Preparation of periplasmic fractions 
An overnight culture, grown in the appropriate antibiotics and 0.2% glucose, was 
sub-cultured 1:100 into media containing the appropriate antibiotics and 0.02% glucose. 
Following growth at 37°C, shaking, to OD600 ~0.5, cultures were induced with 0.4% 
arabinose and grown overnight at 30°C. Induced cultures were normalized by OD600 and 
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resuspended in ice-cold Buffer F (20% sucrose, 30 mM Tris pH 8.5, 1 mM EDTA, 1 g/L 
lysozyme) to a final concentration of 10 OD600/mL and incubate at 4°C with gentle 
agitation for 2hr.  Following centrifugation at 10,000xg for 10 minutes, the supernatant 
was collected as the periplasmic fraction.   
 
Western blot analysis 
Expression and glycosylation of AcrA, Cj0114 and scFv13-R4-GT was analyzed 
by immunoblot following SDS–PAGE of the periplasmic fraction. Immunodetection was 
performed with monoclonal anti-His antibody (Abcam, Cambridge, MA), and polyclonal 
anti-glycan serum hR6 (S. Amber and M. Aebi, personal communication).  
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Conclusions 
 
 
 We have demonstrated the ability of E. coli to express functional OSTs from a 
variety of bacterial species, including nine Campylobacter species, W. succinogens, S. 
denitrificans, Sulfurovum sp, H. pullorum and three Desulfovibrio species.  As far as we 
are aware, this is the first report of the functional expression in E. coli for many of these 
OSTs, including the OSTs from C. upsaliensis, C. concisus, C. fetus, C. gracilis, C. 
hominis, W. succinogens, S. denitrificans, Sulfurovum sp, D. gigas, and D. vulgaris. 
Interestingly, OSTs from the more distantly related H. pullorum, particularly the MIT 
subspecies, exhibited efficient glycosylation of the C. jejuni substrates.   
OSTs from the Desulfovibrio species did not prove capable of glycosylating the 
native C. jejuni substrates, contrary to published data155, likely due to differences in 
expression conditions.  However, the OSTs from each of the three Desulfovibrio species 
were capable of glycosylation of the scFvR4-AQNAT construct at two sites.  While the 
specific identity of the individual sites that were glycosylated by these OSTs were not 
elucidated in these studies, these data provide evidence that the Desulfovibrio OSTs 
recognize a glycosylation consensus sequence that is different from that of the well-
characterized C. jejuni OST. 
 A variety of different factors influence the function of OSTs, from expression 
levels of the various components of the system, to the specific induction conditions 
implemented, making engineering E. coli to reliably perform N-linked glycosylation a 
nontrivial task.  Because E. coli are well understood and thoroughly characterized, 
overcoming these challenges will prove possible.  One way to improve the reliability of 
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this system is to integrate the major components of the glycosylation machinery into the 
genome of an appropriate E. coli strain, increasing the stability of the glycosylation 
machinery by decreasing plasmid stress on cells.   
 The data presented here is a preliminary analysis of the functional 
characterization of bacterial OSTs in E. coli.  Suggestions for the future directions of this 
work are presented in Chapter 5 of this thesis.  
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CHAPTER 4 
A PROKARYOTE-BASED CELL-FREE TRANSLATION SYSTEM THAT 
EFFICIENTLY SYNTHESIZES GLYCOPROTEINS 
 
 
 
Introduction 
1Cell-free protein-synthesizing systems are emerging as an attractive alternative to 
conventional expression systems that rely on living cells (for a review, see 159). This is 
because, over the past decade, cell-free protein synthesis reactions: (i) can be completed 
in less than a day; (ii) use reagents whose costs are down; (iii) fold complex proteins by 
routinely forming disulfide bonds; and (iv) can be scaled to 100 L. Two main approaches 
have been used for in vitro transcription/translation: one is based on cell-free extracts 
(CFEs), often derived from Escherichia coli, rabbit reticulocytes or wheat germ and the 
second is based on reconstituted protein synthesis from purified components160. 
Because of their ability to co-activate multiple biochemical networks in a single 
integrated platform161, cell-free systems are increasingly used in many important bio- 
technology and synthetic biology applications 162–164. 
 The ability to accurately and efficiently glycosylate proteins in a cell-free system 
would have advantages for many areas of basic and applied research, especially given the 
importance of N-linked glycosylation in protein folding, quality control, sorting, 
degradation, secretion and activity165. Unfortunately, the best characterized and most !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!1!Adapted!with!permission!from!Guarino,!C.!&!DeLisa,!M.!P.!A!Prokaryote@Based!Cell@Free!Translation!System!That!Efficiently!Synthesizes!Glycoproteins.!
Glycobiology!22,!596–601!(2012).!!
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widely used cell-free translation systems based on E. coli are incapable of making 
glycoproteins because E. coli lack glycosylation machinery. Likewise, rabbit reticulocyte 
and wheat germ CFE systems cannot perform this post-translational modification because 
they lack microsomes166. This can be overcome by supplementing eukaryotic CFEs with 
microsomal vesicles (e.g. canine pancreas microsomes167,168), but the resulting systems 
do not always faithfully process the target protein due to poor compatibility between 
some CFEs and microsomal vesicles168,169. An alternative strategy for creating a cell-free 
translation system that can execute N-linked glycosylation is to prepare CFEs from 
specialized cells such as hybridomas170, trypanosomes169, insect cells166 or mammalian 
cells171. However, these systems are technically difficult to prepare and typically result in 
inefficient glycosylation and low product yields. Moreover, in all the above systems, the 
glycosylation process is effectively a “black-box” and thus difficult to control. 
To address these issues, two novel cell-free translation/glycosylation systems—
termed “glycoCFE” and “glycoPURE”— were created here by combining existing in 
vitro translation systems with a reconstituted N-linked glycosylation pathway. Purified 
glycosylation components were derived from the protein glycosylation locus (pgl) present 
in the genome of the Gram-negative bacterium Campylobacter jejuni. This gene cluster 
encodes an N-linked glycosylation system that is functionally similar to that of 
eukaryotes and archaea, involving an OST that catalyzes the en bloc transfer of 
preassembled oligosaccharides from lipid carriers onto asparagine residues in a conserved 
motif [N-X+1-S/T in eukaryotes and D/E-X−1-N-X+1-S/T in bacteria42, where X−1 and 
X+1 are any residues except proline] within polypeptides (Figure 1.1). Several 
observations suggested that the C. jejuni glycosylation machinery was ideally suited for 
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use in a cell-free translation/glycosylation system. First, E. coli transformed with the 
entire pgl gene cluster can perform N-linked protein glycosylation17, thereby providing a 
convenient host for producing the necessary components in a pure and active form. Since 
E. coli lacks native glycosylation machinery, the potential for contamination from 
background N- or O-linked systems is eliminated. Second, C. jejuni OST, named PglB 
(CjPglB), is a single-subunit enzyme that is active when solubilized in detergent71 and, 
unlike the homologous STT3 subunit of higher organisms, does not require any accessory 
components for its activity. Third, CjPglB can transfer sugars post-translationally to 
locally flexible structures in folded proteins70, suggesting that protein glycosylation can 
be achieved without supplementing a functional membrane system (e.g. microsomes). 
 
Results 
Preparation of N-linked glycosylation components 
  To begin, functional reconstitution of bacterial N-linked glycosylation in vitro 
was attempted. Minimally, this required three components: an OST, a lipid-linked 
oligosaccharide (LLO) and an acceptor protein carrying the D/E-X−1-N-X+1-S/ T motif. 
For the OST, CjPglB was expressed in the membrane fraction of E. coli cells, solubilized 
with 1% N-dodecyl-β-D-maltopyranoside (DDM) and purified to near homogeneity by 
nickel affinity chromatography followed by gel filtration (Supplementary data, Figure 
S4.1). Separately, E. coli cells carrying the C. jejuni pgl locus were used for producing 
the oligosaccharide donor. This gene cluster encodes enzymes that carry out the 
biosynthesis of a GlcGalNAc5Bac heptasaccharide (where Bac is bacillosamine) and its 
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transfer from membrane-anchored UndPP to asparagine residues. Here, a modified 
version of this cluster that carried an inactivated pglB gene17 was transferred to E. coli 
SCM6 cells and used to prepare LLOs. SCM6 cells were chosen for several reasons. 
First, these cells lack the WaaL enzyme that naturally transfers oligosaccharides (e.g. O-
antigens, glycans) from the lipid carrier UndPP onto lipid A, which in turn shuttles the 
oligosaccharides to the outer leaflet of the outer membrane41. Thus, in the absence of 
WaaL, the desired lipid-linked glycans accumulate in the inner membrane. Second, the 
LPS and enterobacterial common antigen initiating GlcNAc transferase, WecA, is 
removed. Thus, this strain should only produce LLOs with GlcGalNAc5Bac at the 
reducing end. In support of this notion, previous mass spectrometry analysis of LLOs 
extracted from an E. coli strain similar to the one used here (i.e. ΔwaaL ΔwecA) revealed 
that only LLOs containing GlcGalNAc5Bac heptasaccharide were detected172. For the 
oligosaccharide acceptor, the model glycoprotein AcrA from C. jejuni148 was purified 
from the periplasm. AcrA presents two consensus D/E-X1-N-X2-S/T sites that are 
glycosylated by CjPglB42. Alternatively, a glycoengineered single-chain variable 
fragment (scFv) called scFv13-R4-GT, which carried a C-terminal glycosylation tag (GT) 
consisting of four consecutive DQNAT motifs separated from one another by consecutive 
glycine residues42, was similarly purified. 
 
Functional reconstitution in vitro of the C. jejuni protein glycosylation pathway  
To evaluate the reconstituted glycosylation pathway, CjPglB OST was combined 
with LLOs extracted from E. coli cells and purified AcrA. This reaction resulted in 
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efficient glycosylation of both AcrA sites as evidenced by the mobility shift of nearly all 
of the AcrA from the unmodified (g0) to the fully glycosylated (g2) form (Figure 4.1A). 
This activity was dependent on PglB and LLOs. Doubling the LLO concentration 
resulted in the appearance of the g0 and g1 forms of AcrA, in addition to g2, suggesting 
slightly less efficient glycosylation. Importantly, glycosylation activity was lost when 
lipid extracts from cells lacking the pgl cluster or an inactive CjPglB mutant was used 
(Figure 4.1A). These results were corroborated by detecting glycosylated AcrA with 
serum specific for the C. jejuni N-glycan (Figure 4.1A). Nearly identical results were 
observed when the glycoengineered scFv13-R4-GT protein was used as the 
oligosaccharide acceptor (Figure 4.1A). It should be noted that g2, g3 and g4 were the 
predominant glycoforms detected here, with barely detectable levels of g1. To 
demonstrate that other OSTs could be used in this system, in vitro glycosylation of AcrA 
was also performed using Campylobacter lari PglB (ClPglB), which is 56% identical to 
that of C. jejuni154. This resulted in nearly equal amounts of the g0, g1 and g2 forms of 
AcrA under the conditions tested (Figure 4.1B). To be useful for translation/glycosylation 
reactions, the purified glycosylation components must tolerate long-term storage and 
freeze-thaw cycles. To test this, the components were stored separately at −20°C for 3 
months. No changes were made to the storage buffers except that the final concentration 
of glycerol in the PglB samples was increased to 10%. Each of the components was 
thawed and refrozen 5–10 times during this period, after which an in vitro reaction with 
ClPglB was performed. This reaction yielded the glycosylation of AcrA that appeared to 
be only slightly less efficient than the glycosylation observed with freshly purified 
components (compare Figure 4.1B and C). 
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Figure 4.1. Reconstituted glycosylation with defined components. (A) In vitro 
glycosylation assay using purified OST, extracted LLOs and purified acceptor proteins produced 
in E. coli. Immunoblots detecting acceptor protein AcrA and scFv13-R4-GT (both anti-His) or 
glycans (anti-glycan). Reactions included 3 µg wild-type CjPglB, 5 (+) or 10 (++) µL of LLOs 
and 5 µg of acceptor protein. Controls included the omission of different components (−), 
inactivated PglB (mut) and LLOs from SCM6 cells with empty pACYC (+/−). Glycosylation 
yields a mobility shift from the unmodified (g0) to the glycosylated forms (g1 and g2). (B) Same 
as in (A) but with purified ClPglB. (C) Immunoblot detecting AcrA following in vitro 
glycosylation using 3-month-old freeze-thawed components.  
 
Cell-free translation of protein targets 
To determine whether existing cell-free translation systems could synthesize 
protein targets of interest, both an E. coli CFE-based protein synthesis system and the 
PURE (protein synthesis using recombinant elements) system that uses purified 
translation components and T7 RNA polymerase160 were evaluated. This involved 
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priming the CFE and PURE systems with three different AcrA DNA sequences cloned in 
a T7 promoter-driven pET vector. Using the CFE system, ~150–250 µg/mL of each AcrA 
variant was produced as a full-length polypeptide in 1 h (Figure 4.2A). AcrA carrying its 
native signal peptide accumulated to the highest level but also experienced the greatest 
amount of degradation. In contrast, AcrA carrying a PelB signal peptide in place of the 
native signal and AcrA lacking a signal peptide each accumulated to a slightly lower 
concentration but experienced no visible degradation. The PURE system similarly 
produced all three AcrA variants as full-length polypeptides albeit at a slightly lower 
level (~100 µg/mL/h of each) than the CFE-based system (Figure 4.2A). Both systems 
were also able to generate appreciable amounts of scFv13-R4-GT (Supplementary data, 
Figure S4.2a). It should be noted that this scFv was previously optimized for expression 
under non- oxidizing conditions (i.e. in the absence of disulfide bonds)173 and thus did not 
require special transcription/translation conditions. 
! 76!
 
 
 
Figure 4.2. Cell-free translation/glycosylation of AcrA. (A) Immunoblot detecting 
different AcrA constructs (anti-AcrA) produced by in vitro translation using either E. coli CFEs 
or purified translation components (PURE). AcrA concentration was estimated by comparing 
band intensities to that of purified AcrA loaded in lane 1. (B) Immunoblot detecting ΔssAcrA 
expression (anti-AcrA) and glycosylation (anti-glycan). ΔssAcrA was produced by cell-free 
translation/glycosylation using either the CFE or the PURE systems that were primed with 
pET24(AcrA-cyt). Controls included the omission of different components (−) or LLOs from 
SCM6 cells with empty pACYC (+/−).  
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Cell-free translation and glycosylation of target  glycoproteins 
  Encouraged by these results, the glycoCFE and glycoPURE 
translation/glycosylation systems were constructed by combining the purified 
glycosylation components (minus the acceptor protein) with one of the cell-free 
translation systems. The plasmid pET24 (AcrA-cyt) that encodes AcrA without an N-
terminal signal peptide was chosen to evaluate these systems because it gave rise to 
significant amounts of target protein in both translation systems with no detectable 
degradation. When either the CFE or the PURE system were primed with this plasmid 
along with CjPglB and LLOs, AcrA was produced primarily as the doubly glycosylated 
g2 glycoform with lesser amounts of g1 and virtually no detectable unmodified AcrA 
(Figure 4.2B). It was estimated that ~100–150 µg of glycosylated AcrA was produced in 
a 1 mL reaction volume after 12 h. Likewise, scFv13-R4-GT was efficiently produced by 
both the glycoCFE and glycoPURE systems, with ~50% of the protein in the fully 
glycosylated g4 form and 50% in the g3 form (Supplementary data, Figure S4.2b). Both 
systems produced ~50–100 µg/mL of glycosylated scFv13-R4-GT in 12 h. Thus, the 
glycoCFE and glycoPURE systems contain all the components essential for efficiently 
translating N-linked glycoproteins. 
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Discussion 
A major advantage of the open prokaryote-based translation/ glycosylation 
systems developed here is that the supply of purified glycosylation components as well as 
their substrates and cofactors71 can be provided at precise ratios. Likewise, the 
concentration of inhibitory substances such as proteases and glycosidases that catalyze 
the hydrolysis of glycosidic linkages can be reduced or eliminated entirely. Additionally, 
the in vitro systems permit the introduction of components that may be incompatible with 
in vivo systems such as certain LLOs that cannot be produced or flipped in vivo. This 
level of controllability is unavailable in any previous translation/glycosylation system and 
is significant for several reasons.  
First, it helps to avoid glycoprotein heterogeneity, which is particularly 
bothersome in fundamental studies to assess the contribution of specific glycan structures 
or in pharmaceutical glycoprotein production. Along these lines, the glycoCFE and 
glycoPURE systems should allow the examination of factors that interact with or 
stimulate the glycosylation machinery and promote increased acceptor site occupancy. 
While the glycosylation efficiency observed here with CjPglB exceeded the level 
typically observed in vivo42,69,70 it should be pointed out that further study of the reaction 
conditions should lead to increases in productivity and glycosylation efficiency. Second, 
it facilitates the integration/co-activation of multiple complex metabolic systems and 
pathways in vitro including transcription, translation, protein folding and glycosylation. 
Therefore, the glycoCFE and glycoPURE systems should provide a unique opportunity 
for studying the interplay of these important mechanisms under conditions where system 
complexity is reduced and structural barriers are removed. For instance, since the 
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bacterial OST can glycosylate locally flexible structures in folded proteins70 and also 
structured domains of some proteins174, these systems should help to decipher the 
influence of protein structure on glycosylation efficiency.  
Also, since bacterial and eukaryotic glycosylation mechanisms display significant 
similarities, these bacterial systems could provide a simplified model framework for 
understanding the more complex eukaryotic process. Third, it allows for further 
customization of the system by re- constituting additional or alternative steps (both 
natural and unnatural) in the glycosylation pathway. For instance, the sequential activities 
of the glycosyltransferases in the pgl pathway have been reconstituted in vitro46 and 
could easily be integrated with the translation/glycosylation reactions into a single 
integrated platform. While glycoengineered E. coli have the potential to provide a wide 
array of UndPP-linked glycans41,175, the ability to extend beyond bacterial glycans could 
be achieved by supplementation with specific glycosyltransferases and the requisite 
activated sugars. This approach could be used for making eukaryotic glycan mimetics176 
and would allow finer control over the diversity of glycoforms that can be used for 
modifying target proteins in vitro. Since CjPglB has relaxed specificity toward the glycan 
structure41, all of these UndPP-linked glycans are likely to be suitable substrates. Even if 
CjPglB should prove insufficient, the demonstration here that two different OSTs could 
be used interchangeably suggests that virtually any single-subunit OST including those 
from other bacteria, archaea and even some eukaryotes61 could be used in these systems. 
In support of this notion, the Leishmania major and Pyrococcus furiosus single-subunit 
OSTs can be functionally expressed in E. coli membranes177,178.  
Finally, because one is not limited to natural glycans, the glycoCFE and 
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glycoPURE systems should permit synthesis of hybrid natural/unnatural or even 
completely artificial glycans. For example, the addition of synthetic sugar-nucleotide 
donor substrates and/or mutant glycosyltransferases and OSTs having new specificities 
should enable the construction of a glycosylation system founded on a noncanonical 
glycan code. For all of these reasons, we anticipate that the glycoCFE and glycoPURE 
systems will be useful additions to the cell-free translation and glycobiology tookits alike. 
 
Materials and methods 
Protein purification 
For the purification of CjPglB, E. coli strain C43(DE3) (Lucigen, Middleton, WI) 
was freshly transformed with plasmid pSN1870, a modified pBAD expression plasmid 
encoding C. jejuni pglB with a C-terminal decahistidine affinity tag. Cells were grown in 
1.5 L of terrific Broth supplemented with 100 µg/mL of Amp at 37°C. When the optical 
density (A600) of the culture reached ~1.0, cells were induced by the addition of 0.02% 
arabinose (w/v) for 4.5 h at 30°C. All following steps were performed at 4°C unless 
specified differently. Cells were harvested by centrifugation, resuspended in 25 mM Tris, 
pH 8.0, and 250 mM NaCl and lysed by three passages through a French press (SLM-
Aminco; 10,000 PSI, SLM Instruments, Inc., Urbana, IL). Following the removal of cell 
debris by centrifugation, the membrane fraction was isolated by ultracentrifugation at 
100,000 × g for 1 h. Membranes containing PglB were resuspended in 25 mM Tris–HCl, 
pH 8.0, 250 mM NaCl, 10% glycerol (v/v) and 1% DDM (w/v) (DDM, Anatrace, 
Affymetrix, Inc., Santa Clara, CA) and incubated for 2 h. The insoluble fraction was 
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removed by ultracentrifugation at 100,000 × g for 1 h. All subsequent buffers contained 
DDM as the detergent. The solubilized membranes were supplemented with 10 mM 
imidazole, loaded onto a Ni-NTA superflow affinity column (Qiagen, Valencia, CA) and 
washed with 60 mM imidazole before PglB was eluted with 200mM imidazole. The 
purified protein was then injected onto a Superdex 200 gel filtration column using 
AKTA-FPLC (GE Healthcare, Waukesha, WI). Eluate fractions were subjected to 
sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS–PAGE) and stained 
with Coomassie blue to identify the fractions containing PglB (Supplementary data, 
Figure S4.1). The protein was desalted with a PD10 desalting column (GE Healthcare) 
into 20 mM Tris, pH 7.5, 100 mM NaCl, 5% glycerol (w/v) and 0.05% DDM (w/v) and 
concentrated to 5–10 mg/mL in an Amicon centricon with a molecular mass cutoff of 
100kDa. Expression and purification of the inactive CjPglB mutant was performed 
identically in C43(DE3) cells except carrying plasmid pSN18.1, which encodes an 
inactive copy of pglB subcloned from pACYCpglmut (see below), were used. ClPglB 
was purified from BL2-Gold(DE3) cells (Stratagene, La Jolla, CA) carrying plasmid 
pSF2 as described elsewhere71. For long-term storage at −20°C, the glycerol content in 
PglB samples was increased to 10% (w/v). 
Purification of AcrA and scFv13-R4-GT was from periplasmic fractions isolated 
from BL21(DE3) cells carrying plasmid pET24(AcrA-per)148 or pET24-ssDsbA- scFv13-
R4-GT (see below). Periplasmic extracts were prepared as described previously154, 
supplemented with imidazole to reach a final concentration of 10 mM, sterile- filtered 
(0.22 µm) and purified by nickel affinity chromatography using Ni-NTA superflow 
affinity column (Qiagen, Valencia, CA). 
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Isolation of LLOs  Escherichia coli SCM6 cells transformed with 
pACYCpglmut17, which codes for the biosynthesis of the C. jejuni LLO and an 
inactivated C. jejuni pglB gene (W458A and D459A), were grown in 1 L of Luria-
Bertani supplemented with 25 µg/mL of Cm at 37°C. When the A600 reached ~1.0, cells 
were harvested by centrifugation and the pellet was lyophilized to dryness for 20 h at 
−80°C and 0.04 mbar. All subsequent steps were performed using glass tubes and glass 
pipettes. Homogenized pellets were extracted in 25 mL of 10:20:3 CHCl3:MeOH:H2O 
followed by centrifugation at 3000×g for 30min. The supernatants were evaporated using 
a rotary evaporator (Büchi, Flawil, Sankt Gallen, Switzerland), after which the resulting 
pellet was resuspended in 1 mL of 10:20:3 CHCl3:MeOH:H2O and sonicated until 
homogenous. The sample was dried under nitrogen gas at 37° C, dissolved in 10 mM 
HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid), pH 7.5, 1 mM MnCl2 and 
0.1% DDM (w/v) and stored at −20°C. An identical procedure was followed to extract 
lipids from SCM6 cells carrying empty pACYC. 
Cell-free translation and glycosylation 
For in vitro glycosylation of purified acceptor proteins, a 50 µL solution 
containing 3 µg of purified PglB, 5–10 µL of extracted LLOs and 5 µg of purified AcrA 
or scFv13-R4-GT in 10 mM HEPES, pH 7.5, 1 mM MnCl2 and 0.1% DDM (w/v) was 
incubated for 12 h at 30°C. For in vitro translation of AcrA and scFv13-R4-GT in the 
absence of glycosylation, a 50 µL reaction was prepared using the S30 T7 High-Yield 
Expression System (Promega, Fitchburg, WI) or PURExpress (New England Biolabs, 
Ipswich, MA) according to the manufacturer’s instructions. A total of 1 µg of the 
following plasmids were added to each reaction: pET24b (Novagen, Madison, WI); 
! 83!
pET24-AcrA encoding full-length C. jejuni AcrA with a C-terminal hexahistidine tag148; 
pET24(AcrA-per) encoding a version of AcrA with an N-terminal PelB signal peptide in 
place of its native export signal148; pET24(AcrA-cyt) encoding a version of AcrA without 
an N-terminal export signal (ΔssAcrA)148 and pET24- ssDsbA-scFv13-R4-GT encoding 
the expression-optimized scFv13-R4 intrabody gene173 with an N-terminal signal peptide 
from E. coli DsbA for secretion and a C-terminal GT69 followed by a FLAG and a 
hexahistidine epitope tag. For in vitro translation/glycosylation reactions, 50 µL of 
translation reactions was supplemented with 3 µg purified PglB, 5 µL extracted LLOs, 1 
µg purified plasmid DNA, 1 mM MnCl2 and 0.1% DDM (w/v) and incubated for 12 h at 
30°C. DDM was chosen for in vitro translation/glycosylation because it was previously 
observed to be well tolerated in an E. coli-derived CFE system179. 
Western blot analysis 
Expression and glycosylation of AcrA and scFv13-R4-GT was analyzed by 
immunoblot following SDS–PAGE. Immunodetection was performed with monoclonal 
anti-His antibody (Qiagen, Valencia, CA), monoclonal anti-FLAG antibody (Abcam, 
Cambridge, MA), polyclonal anti-AcrA serum17 and polyclonal anti-glycan serum 
hR6177. All in vitro translation samples were treated with RNase A (Roche Diagnostics 
GmbH, Mannheim, Germany) prior to SDS–PAGE to reduce the irregularity of gel 
electrophoresis due to excess RNA. All experiments were performed at least in triplicate, 
and representative samples are shown. 
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Supplementary data 
 
Supplemental Figure S4.1. Purification of bacterial OST. CjPglB was expressed in E. 
coli C43(DE3) cells and purified to near homogeneity. Elution fractions (as indicated) from gel 
filtration columns were examined by SDS-PAGE, and the Coomassie Blue-stained gel images (b) 
are shown together with the elution profiles (a). MW, molecular weight standard. 
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Supplemental Figure S4.2. Cell-free translation/glycosylation of scFv13-R4-GT. (a) 
Immunoblot detecting different scFv13-R4-GT (anti-FLAG) produced by in vitro translation 
using either E. coli cell-free extracts (CFE) or purified translation components (PURE). Estimates 
of the scFv13-R4-GT concentration were determined by comparison of band intensities to that of 
the purified scFv13-R4-GT sample loaded in lane 1. (b) Immunoblot detecting scFv13-R4-GT 
expression (anti-FLAG) and glycosylation (anti-glycan). The scFv13-R4-GT protein was 
produced by cell-free translation/glycosylation using either the CFE or PURE systems that were 
primed with pET24-ssDsbA- scFv13-R4-GT. Controls included omission of different 
components (-). 
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CHAPTER 5 
CONCLUSIONS AND FUTURE DIRECTIONS 
 
 
 
 Significant progress has been made in our understanding of the process of N-
linked glycosylation since the advent of the works described in this thesis. It is now clear 
that a wide variety of bacterial species have the ability to N-glycosylate proteins26, and 
we have shown that many of the OSTs from these organisms function in E. coli.  Further, 
it is now possible to produce the core Man3GlcNAc2- structure of the eukaryotic glycan 
in E. coli23, and we have developed methodologies that could be extended to select for 
functional variants of OSTs that more efficiently transfer that glycan onto protein.  
Finally, in vitro assays for OST activity have been developed150, and our in vitro system 
further simplifies the model framework for glycosylation43. Here, I present several ideas 
for future work in this field, followed by a summary of the works presented thus far.  
 
 
Improving therapeutic protein production in Escherichia coli 
 
 Unlike mammalian cells and yeast, E. coli do not require glycosylation in order to 
survive.  This along with their ease of culture makes them the ideal candidate for 
engineering glycosylation machinery to produce both specific and unique glycoproteins. 
Examples of modifications that could be engineered into E. coli to improve their 
therapeutic protein production potential are elucidated here. 
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 Two of the main challenges associated with the production of therapeutic proteins 
are their lack of stability when stored over prolonged periods and rapid degradation 
and/or clearance from the body once administered.  One solution that has begun to 
overcome these challenge is PEGylation.  PEGylation is a process in which polyethylene 
glycol (PEG) chains are added to a protein, effectively increasing the protein’s molecular 
weight and shielding it from degradation by proteolytic enzymes, leading to prolonged 
shelf-life and increase half-life in vivo180.  The original PEGylated proteins were 
heterogeneous mixtures, with different numbers of PEG molecules and linkages, but 
regulations now require specific homogeneous conjugations to achieve approval181. 
Currently, PEG can be specifically added to the N-terminus, free cysteine residues182, 
unnatural amino acids 183, disulfide bridges184, the C-terminus185, and glutamine 
residues186.  However, it is possible that certain modifications, such as the addition of 
cysteine residues or modified amino acids, could negatively impact protein function.  
Another possibility for site-directed PEGylation of proteins is through attachment to a 
glycan.  This process is known as glycoPEGylation and can be used to incorporated PEG 
at a specific location in a protein normally occupied by a glycan, and therefore less likely 
to interfere with the active site181.   
GlycoPEGylation has been demonstrated by enzymatic conjugation in vitro of a 
GalNAc monosaccharide to specific serine or threonine residues of non-glycosylated 
proteins produced from E. coli. The GalNAc monosaccharides are then conjugated to 
PEG by enzymatic transfer of a sialylated PEG molecule187.  A similar, though more 
complex, procedure was developed for the glycoPEGylation of complex mammalian N-
linked glycans attached to glycoproteins expressed from CHO cells188.   Recently, a 
! 88!
protein modified using this technology has entered clinical trials189.  Utilizing the 
glycosylation capabilities of engineered E. coli, it should be possible to create N-linked 
glycans than can be easily linked to PEG for increased stability of therapeutic proteins.   
The native WecA protein from E. coli is capable of transferring a GlcNAc to the 
UndPP lipid carrier23,190, and it has been demonstrated that this residue can replace 
bacillosimine as the aspargine-linked sugar residue of the C. jejuni oligosaccharide191. 
Therapeutic proteins should not contain bacillosimine, as this monosaccharide is not 
found in humans, and it would likely prove to be immunogenic.  PglA is the enzyme in 
the C. jejuni glycosylation pathway that transfers the first GalNAc residue onto 
bacillosimine192, and based on the successful construction of the C. jejuni oligosaccharide 
without bacillosimine, it is evident that it can also transfer GalNAc onto GlcNAc.  Since 
the C. jejuni OST is capable of transferring the GalNac-Bac- disaccharide onto peptides 
in vitro151, it should also transfer a GalNAc-GlcNAc- disaccharide onto proteins. 
Therefore, it should be possible to engineer E. coli to produce proteins with the N-linked 
GalNAc-GlcNAc- disaccharide by simply co-expressing PglA, PglB, and a therapeutic 
protein candidate with an N-linked glycosylation consensus sequence. PEG could be 
conjugated specifically to this glycoprotein using a single enzymatic step, simplifying the 
previously described method187. 
 It may also be possible to create more stable therapeutic glycoproteins from 
bacteria without the addition of PEG. The primary benefits of PEGylation are the lack of 
immune response to PEG and the increase in molecular mass of the target protein. Instead 
of PEG, large polysaccharide chains could be added to specific sites in proteins, 
eliminating the in vitro conjugation step.  O-antigens provide a viable template for such 
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large polysaccharides, however most O-antigens also have a high likelihood of initiating 
an immune response in the host.  Clever engineering of these sugars will be necessary for 
this type of modification to have a positive impact on protein therapeutics. First, a core 
non-immunogenic structure would have to be engineered, mimicking standard structures 
found in the human body. Next, O-antigen polymerases such as Wzy193, would have to be 
engineered to recognize and polymerize the non-immunogenic subunit.  Finally, to 
maintain homogeneity of chain length, regulators of O-antigen chain length194 would 
have to be engineered to recognize the novel substrate. 
 
 
Uncovering glycosylation site specificity in bacterial OSTs 
 
 In order to exploit E. coli as a host for production of therapeutic proteins, it would 
be ideal to have a larger set of enzymes to work with an not be limited to OSTs that 
require extended sequence modifications for efficient glycan transfer.  In our comparative 
analysis of bacterial OSTs, we discovered OSTs with altered glycosylation acceptor site 
specificity.  The most interesting of these OSTs are those from the Desulfovibrio genus.  
These OSTs were demonstrated to be capable of transferring the C. jejuni oligosaccharide 
onto a model protein that did not contain the typical bacterial N-linked glycosylation 
consensus sequence.  In order to determine the specific sites glycosylated by these 
enzymes, a combination of site-directed mutagenesis and mass-spectrometry has been 
proposed.  While these methods will allow us to determine the specific sites glycosylated 
by these enzymes in this particular protein, the information we obtain will only represent 
a subset of all of the possible sites that these enzymes can recognize. 
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 Here, I propose a method for rapid determination of the glycosylation site 
specificity of any OST that can be expressed in E. coli, native or engineered. The method 
involves a novel implementation of the phage display technology described in Chapter 2 
of this thesis. The significance of the proposed method is two-fold: (i) the specific 
consensus sequences recognized by many of the OSTs discussed in this thesis are 
currently unknown, and novel glycosylation sites could prove useful in glycoprotein 
engineering, furthermore (ii) OSTs that are engineered to recognize novel sequences 
could be inadvertently altered to recognize unexpected sequences, and the screening 
methods proposed here will be useful for more thorough, high-throughput 
characterization of engineered OSTs.  
 The concept behind the proposed method is the design of a library of peptides 
containing potential glycosylation sites. The size of the peptide library is limited by the 
transformation efficiency of E. coli, where the maximum expected library size is 
approximately 109.  We could make the assumption that all OSTs recognize N-X-(S/T) 
sites, but this may not be true, therefore I propose a library of random peptides, each 
containing a central asparagine residue, flanked by three randomized amino acids on 
either side.   For full coverage of this library, ten transformations would need to be 
combined.  
 It has been shown that phage expressing a GT-g3p fusion, without the soluble 
MBP protein, but including the signal sequence of MBP (ssMBP) for targeting the 
protein to the periplasm, can be glycosylated and displayed on phage particles98.  
Therefore, to simplify the system, this would be the ideal construct.  The library could 
easily be produced through overlap extension PCR, followed by insertion into the 
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phagemid by the Gibson assemble method195, which avoids the use of restriction enzymes 
that could inadvertently truncate library members. Two complementary primers 
containing the ssMBP sequence, followed by 5’-NNKNNKNNKAATNNKNNKNNK-3’, 
followed by ~20bp of the 5’ end of g3p would be utilized to insert the randomized GT 
into the phagemid construct. 
 Once the phagemid library was produced, it would be transformed into TG1 
ΔwaaL co-expressing the C. jejuni pgl locus without PglB, ideally from the genome, and 
a plasmid encoding the OST to be investigated.  Phage particles would then be produced 
from these cells and selected using the previously described method144.  Following two to 
four rounds of sorting, individual clones would be analyzed for glycosylation.  This could 
be done in a high-throughput method, where phage particles are produced in 96-well 
plates from individual clones, and glycosylated phage are detected in an ELISA format 
(data not shown). Clones capable of glycosylation would be sequenced, and glycosylation 
would be verified by Western blot.  To confirm the specific glycosylation sites, site-
directed mutagenesis and/or mass spectrometry would be performed. 
 This straightforward method could help to elucidate the glycosylation site 
specificities for a variety of OSTs that can be expressed in bacteria.  The discovery of 
novel glycosylation sites will be useful in the future design of glycoproteins in the 
prolific E. coli protein production host.  
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Summary of the presented works 
 
This thesis focused on utilizing E. coli as a host for the study of one of the 
important branches of the field of glycobiology, N-linked glycosylation.  Specifically, the 
emphasis of this research was to further our understanding of and improve the function of 
the OST, the enzyme responsible for catalyzing the transfer of an oligosaccharide onto an 
asparagine residue of a glycoprotein.  The discovery that N-linked glycosylation could be 
engineered into E. coli, an organism that does not require this modification for cell 
survival, opened a unique avenue for the study of this important post-translational 
modification. Furthermore, the advent of glycosylation-competent E. coli has provided a 
new platform for the production of therapeutic glycoproteins and vaccine candidates.   
In order to create OSTs with improved function, it was first necessary to develop 
a selection tool that could be utilized to isolate variants with the desired glycosylation 
phenotype, while maintaining a genotype linkage.  A variety of approaches have been 
taken towards this goal, three of which were described here.  The most promising tool 
developed was the glycophage display system98, which was implemented for the selection 
of bacterial OSTs with relaxed acceptor site specificity.  Although the phage display 
system requires further development in order to stabilize the components to more 
effectively select for functional variants of OSTs, it should prove useful in the future.  
Additionally, a variation of this technology was presented for the efficient elucidation of 
bacterial OST acceptor site specificity.  
The C. jejuni OST and the closely related C. lari OST are the most thoroughly 
characterized of the bacterial OSTs to date.  As more bacterial genomes are sequenced, it 
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is expected that many other species will contain genes with significant homology to these 
Campylobacter enzymes.  In an effort to discover OSTs with novel function, a variety of 
bacterial OSTs were expressed in E. coli.  Each of these OSTs was tested for its ability to 
transfer the C. jejuni glycan onto different protein substrates.  Several OSTs with altered 
acceptor site specificity where discovered, and methodologies for further characterizing 
these enzymes have been proposed.    
In order to more thoroughly characterize OSTs, an in vitro system was developed 
that simplifies the model framework of glycosylation43.  The reduced complexity of the in 
vitro system allows for closer investigation of each component of the glycosylation 
machinery.  By combining cell-free translation systems with a plasmid encoding a 
glycoprotein and adding LLOs and purified OST, we efficiently produced glycosylated 
proteins. This method could be utilized to introduce components that are incompatible 
with the in vivo system, such as unnatural or even artificial glycans.  The system was 
proven to be compatible with both the C. jejuni OST and the C. lari OST, so it follows 
that it should be useful for observing the function of a variety of other single-subunit 
OSTs. 
E. coli has proven to be a useful tool for developing a more thorough 
understanding of N-linked glycosylation.  Continued research in the field of bacterial 
glycosylation will undoubtedly lead to new and remarkable discoveries with significant 
impact on the biopharmaceutical industry.   
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CHAPTER 6 
EXPANDING THE HORIZONS:  
BIOLOGICAL ENGNEERING FOR THE NEXT GENERATION 
 
 
Introduction 
 
The National Science Foundation GK-12 program, collaborating with university 
institutions, provides financial support to graduate students enrolled in science, 
technology, engineering and mathematics (STEM) programs. Cornell’s Learning 
Initiative in Medicine and Bioengineering GK-12 (CLIMB) program is such a program. 
The CLIMB program partners science teachers in middle and high schools in surrounding 
school districts with graduate fellows in the field of Biomedical Engineering. The 
Department of Biomedical Engineering at Cornell University, through the CLIMB 
program, provided funding for two years of the aforementioned research.  
Designed to provide more than financial support to graduate student fellows 
during their research, the CLIMB program creates a unique platform in which the 
graduate student can enhance communication expertise, improve research design skills as 
well as develop advanced teaching skills with the ability to translate graduate research for 
a K-12 audience. Furthermore, the program was designed to enhance the scientific 
knowledge base and skill set of K-12 educators and benefit the K-12 students by placing 
a guest scientist in the classroom as an expert and a role model. 
Ronald Reed, a 20-year veteran teacher of Biology and Living Environment at 
Cortland Enlarged City School District in Cortland, N.Y., was my teacher partner during 
my first year in the CLIMB program.  Michelle Kornreich, a sixth grade General Science 
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teacher at Boynton Middle School in Ithaca, N.Y. was my teacher partner during my 
second year in the program. The educators were invited to the Cornell Biomedical 
laboratory at Olin Hall to participate in a six-week summer scientific immersion program. 
During their summer participation they each were expected to conduct a novel scientific 
research project. The teachers also attended BME5875: Frontiers in Biomedical Research 
for Teachers, a class designed to broaden their knowledge of current research endeavors. 
Weekly meetings attended by both educator and fellow addressed teaching 
methodologies, with a strong focus on inquiry-based teaching. At the end of the six-week 
program, the educators were required to present their research in a poster session.  
The CLIMB 2010 summer research project, with Ronald Reed, focused on the 
synthesis and design of carbohydrate microarrays which could be used in both diagnostic 
and research applications. Current methods for production of carbohydrate microarrays 
require expensive techniques for in-vitro carbohydrate production. Here, we proposed a 
method for making a carbohydrate microarray by decorating bacteriophage in vivo with 
carbohydrates, specifically O-antigens originating from pathogenic bacteria, similar to 
the phage display methods described in Chapter 2 of this thesis. The glycophage are 
produced by helper phage infection of cells carrying an O-antigen operon, an OST, and 
the gene for a phage coat protein engineered to contain an N-glycosylation site. 
Specifically, we investigated the ability of phage to display the glycan in higher valiancy 
by fusing the acceptor peptide to the major coat protein, g8p, instead of the minor coat 
protein, g3p. The OST used in this study, C. jejuni pglB, can be functionally expressed in 
non-pathogenic E. coli and can transfer O-antigens onto asparagine residues within 
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specific N-glycosylation sites, as describe in the former chapters of this thesis.  Phage 
expressing the g8p-GT fusion protein did not prove to be glycosylated (data not shown).  
The CLIMB 2011 summer program with teacher partner Michelle Kornreich was 
a different experience. Mrs. Kornreich was trained as an elementary teacher and had 
recently been tasked to teach middle school General Science. Not extensively trained in 
any advanced science, she lacked the basic understanding of the central principles of 
molecular biology. Shortly into the summer immersion program, it became apparent that 
she did not have a sufficient knowledge base to complete the proposed project.  She was 
experiencing frustration, bordering on defeat. This was not the intention of the CLIMB 
program. Therefore, it became necessary to alter the directions of the proposed project. 
We chose to place more focus on developing Michele’s understanding of basic biology, 
and less focus on accomplishing a specific project.  Michelle shadowed me in the 
laboratory, learning about the process of cloning a gene of interest and making mutations 
to DNA that led to variations in protein function.  Specifically, we worked on a project 
that involved creating and testing point mutations of C. jejuni PglB for altered catalytic 
activity. She finished her summer having accomplished a great deal and entered her 
classroom in the Fall with a new passion and appreciation for Science which she passed 
on to her students. 
As part of the intensive summer program, a curriculum centered on 
bioengineering topics was designed. The curriculum specifically connected the teacher’s 
newly acquired scientific knowledge to tangible human health problems, with the 
objective of sparking student interest in the fields of Science and Engineering.  
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The following school year, an average of ten hours per week was spent preparing 
curricular material and working in the teacher partners’ classrooms, developing 
additional teaching and laboratory modules, lecturing and interacting with students, and 
assisting with laboratory and instructional tasks. I also had the opportunity during my 
classroom time to observe each of my educator partners’ teaching techniques to help me 
to craft better highly interactive lesson plans. 
The Integration of the research for the GK-12 experience was challenging as most 
young students view bacteria as pathogens. The lessons began by introducing the fact that 
bacteria, specifically non-pathogenic E. coli, are commonly used as protein production 
hosts, with the capacity to survive while more than 20% of the total protein content is 
composed of foreign protein. Describing proteins such as insulin, which can be produced 
in E. coli and used for therapeutic purposes provided a translation to a concrete concept 
that the students could relate to. One goal of the GK-12 experience was to use this protein 
production host to teach students the central dogma of molecular biology: 
DNA→RNA→Protein in a way that allows them to visualize the process. In the high 
school classrooms, students were challenged to design DNA coding for a fluorescent 
protein. When the cells expressed the protein from their engineered DNA sequence, the 
cells glowed. This exercise engaged and fascinated the students.  
 
What follows are the curriculums developed for a high school Biology class and a 6th 
grade General Science class, respectively.   
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Curriculum 1: 
Cloning a Protein of Interest 
 
Introduction 
 
 This teaching module was designed in collaboration with Ronald Reed, a science 
teacher at Cortland Enlarged City School District in Cortland, NY, for 9th and 10th grade 
students enrolled in Living Environment, aka. Biology. The New York State – Living 
Environment standards covered in this curriculum include: Std. 1. Analysis, inquiry and 
design, Std. 4.2. Genetic inheritance, Std. 4.3. Organisms change over time, and Std. 4.4. 
Continuity of life. 
 The scheduled time frame for this curriculum is 2 periods of 45 minutes each, and 
2 periods of 90 minutes each. 
 
Description 
Students are exposed to recombinant DNA technology and the process of cloning 
a protein of interest.  Starting with the DNA sequence for a gene coding for a fluorescent 
protein, students help design primers to make copies of the gene. Next, students learn 
about gel electrophoresis, which is used to purify the gene copies from a PCR reaction.  
A model ligation reaction activity is used to demonstrate how to construct an expression 
plasmid.  Finally, the students get to work with cells expressing the fluorescent protein(s) 
they helped clone. 
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Objectives 
• Students will develop a deeper understanding of the central dogma of molecular 
biology: DNA ! RNA ! Protein.  
• Students will understand how electrophoresis can be used to separate molecules. 
• Students will be able to describe how to make a protein of interest, and they will be 
able to provide examples of proteins that are of interest to scientists. 
• Students will understand that while many bacteria can make you sick, they can also 
be very useful. 
 
 
Materials 
Hand-outs: 
Part I, PCR; Part II, electrophoresis; Part III, model ligation reaction 
Day 1: Scissors, Codon table 
Day 2: NeoSCI gel electrophoresis kit [components of kit available through BioRad]: 
Four dyes and two unknown mixtures, Agarose, Tris/Borate/EDTA buffer (TBE). 
Electrophoresis chamber and power supply, Micropipette, p20, with tips 
Day 3: Scissors, Tape 
Day 4: LB agar plates with kanamycine and IPTG (kanamycine and IPTG available 
through Sigma), MC4100 E. coli cells containing fluorescent protein expression vectors 
(pET28) [similar expression vectors and comparable competent cells available through 
invitrogen], Micropipette tips and 1.7mL epi-tubes 
Blue light box (for imaging plates from Day 4) 
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Science Content for the Teacher 
     Most people view bacteria as pathogens that make you sick, but not all bacteria 
are bad. In fact, bacteria, specifically non-pathogenic Escherichia coli, are commonly 
used as protein production hosts, with the capacity to produce more than 20% of the total 
protein content as foreign protein. Proteins such as insulin can be produced in E. coli and 
used for therapeutic purposes.  
The primary goal of this curriculum is teach students the central dogma of 
molecular biology: DNA→RNA→Protein in a way that allows them to visualize the 
process.  To clone a protein, on must first obtain a copy of the gene sequence for the 
protein.  Copies are made from a template sequence through a process known as PCR.  
Once the PCR product is copied, it is digested with restriction enzymes and ligated into a 
plasmid that has also been digested with the same enzymes.  A plasmid is a circular piece 
of DNA that contains (1) an origin or replication (to allow the plasmid to be replicated in 
the cells), (2) a gene that confers antibiotic resistance (to force the bacteria to maintain 
the plasmid), and (3) a multiple cloning site (a region flanked with a promoter and 
terminator with numerous restriction enzyme cut sites in between for ease of cloning).   
Students will be given the DNA sequence for a fluorescent protein, and with the 
guidance of the teacher and fellow, they will be challenged to design primers to clone this 
sequence into an expression vector.  Over several days, the students will be exposed to all 
the steps of the cloning process, including separating molecules using gel electrophoresis, 
and an interactive model ligation reaction.  When the protein from the students’ 
engineered DNA sequence is expressed in bacteria, the cells will ‘glow,’ in so much as 
they will convert UV light into green light, which we can see.    
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PCR: 
 Polymerase chain reaction is a methodology used to make many copies of a 
particular gene sequence.  The reaction is composed of the template DNA, primers, 
nucleotide bases (dNTPs), polymerase and a buffer.  By cycling the temperature from 
98°C for 30s to melt the DNA template, to 50-56°C for 30s to anneal the primers, to 68-
72°C for 1min/kb of product to extend, or copy, the template, and repeating this cycle 25-
30 times, millions of copies of the DNA sequence can be made. 
 Polymerase is an enzyme which creates new DNA from 5’to 3’, as it reads a 
sequence 3’ to 5’. The polymerase used in this reaction needs to be heat stable in order to 
survive the temperature cycling of the reaction.  The discovery of a polymerase from 
thermophilic bacteria, which has evolved to withstand exceedingly high temperatures, 
made this possible.  The buffer in the reaction contains magnesium, which is needed to 
stabilize and maintain the structure of the polymerase in order for it to function properly. 
 Primer design is a key element in any PCR.   The primers indicate where the 
polymerase should begin copying, at either the beginning or end of the sequence.  
Therefore, only the region between the primers (a forward primer that is a direct copy of 
the sequence, and a reverse primer that is the reverse complement of the end of the 
sequence) gets copied. Additionally, 5’ overhangs can be added to the primers to 
introduce the DNA sequence for restriction enzyme cut sites at the beginning and end of 
the sequence (Figure 6.1.). 
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Gel Electrophoresis: 
 
 Gel electrophoresis is most commonly used for separation of biological 
macromolecules such as deoxyribonucleic acid (DNA), ribonucleic acid (RNA), or 
protein; however, gel electrophoresis can also be used for separation of nanoparticles and 
small molecules. 
 Electrophoresis refers to the movement of a charged particle in an electrical field. 
Gels suppress the thermal convection caused by application of the electric field, and can 
also act as a sieving medium, retarding the passage of molecules. DNA Gel 
Figure'6.1.!Introduction'to'PCR!
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electrophoresis is usually performed for analytical purposes, often after amplification of 
DNA via PCR, but it may also be used as a preparative technique. 
Following PCR amplification of our DNA encoding the fluorescent proteins we 
are cloning, the DNA was run on a gel.  The DNA fragments, which can be visualized on 
a blue (or UV) light box after staining with a SyberSafe® or Ethidium bromide, were cut 
from the gel to separate our product from the other components of the PCR reaction. 
 
Ligation Reaction: 
 
DNA ligase is an enzyme which will ligate, or join together, two pieces of DNA 
by catalyzing the formation of a phosphodiester bond in the backbone of the DNA.  
 One common way of cloning is to cut a plasmid with restriction enzymes, some of 
which leave overhanging ‘sticky ends,’ and ligate it to DNA coding for your protein of 
interest (POI) which has been cut by the same enzymes (the cut-sites are usually 
introduced to your POI gene sequence by adding 5’ overhangs to the PCR primers).  
Restriction enzymes are enzymes that recognize specific sequences in DNA and cut in a 
specific way.  These enzymes were originally discovered in bacteria and are used by the 
bacteria to digest and destroy foreign DNA.  
 
Pre-requisites 
This module is best taught near the end of the school year, after the students have been 
exposed to the majority of the course material, as there are many opportunities for 
‘making connections’.  Specifically, the students should know where DNA is found in 
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cells, that DNA is double stranded and made-up of nucleotide base pairs, that DNA 
encodes genes that code for protein, that the DNA is transcribed into mRNA before being 
translated into protein, and that proteins are composed of amino acids. This module could 
be easily incorporated into an AP Biology class. 
 
 
Classroom Procedure 
Day 1. Cloning a protein of interest, Part I: PCR 
(45-90 minute class) 
 Begin class by showing an image of an Aequorea victoria jellyfish, the animal in 
which green fluorescent protein (GFP) was originally discovered. Inform the students that 
the fluorescence of this animal is caused by the expression of the GFP protein, and that 
their task is to make bacteria fluoresce by making them produce this protein.  Challenge 
the students to tell you how to make a protein. 
Students should be able to come up with the idea that in order to make a protein, 
we need to start with the DNA sequence for the protein.  Once it is established that we 
need the DNA, introduce the concept of polymerase chain reaction, which will be 
required to make copies of the gene.  One or more videos that describe and animate the 
process can be used.  This includes ‘polymerase chain reaction Animated’, available at: 
http://www.youtube.com/watch?v=HMC7c2T8fVk. 
 Once the students are clear on the basics of PCR, distribute the ‘Cloning a protein 
following a basic introduction to polymerase chain reaction.  Groups of 3-5 students will 
work together to determine which of the primers they have been given will work in a 
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PCR reaction to copy the DNA sequence for their protein of interest.  DNA sequences for 
two proteins are provided. A range of primers that will bind the template, and some that 
will not, are provided.  For ease of alignment, students will be asked to cut-out the primer 
sequences. Some of the primers have mutations, including lacking a start coding or a stop 
codon, and when the students discover these, they will be challenged to determine what 
effect using those primers would have on their final product – a codon table will be 
necessary for the identification of the start and stop codons. Two sets of primers will 
work to copy each template, but one set will add a 5’ overhang at each end to introduce 
restriction enzyme cut sites.  When the students discover these primers, this will lead into 
an introduction to one commonly used type of cloning, involving digestion with 
restriction enzymes.                                                                                        
 
SOLUTIONS:  
1. Forward sequence, 2. Forward sequence with 5’ overhang, 3. Forward sequence 
without start codon, 4. Reverse complement of forward sequence, 5. Reverse sequence, 6. 
Reverse sequence with 5’ overhang, 7. Reverse sequence without stop codon, 8. Reverse 
complement of reverse sequence, 9.Random sequence. 
 
 Students may not have sufficient time in a 45 minute class period, following the 
introduction to PCR, to finish the activity.  In this situation, the answers to the six 
questions should be discussed at the beginning of the next class.  When presenting 
answers, students should be pushed to share their own answers before being given the 
correct answers. 
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Day 2. Cloning a protein of interest, Part II: Gel Electrophoresis 
(45-90 minute class) 
 
Preparation: Have at least one electrophoresis set-up in the classroom, and a gel casting 
set-up ready to go.  Just before class begins, melt the 0.8-1% agarose (in TBE), by 
microwaving (approximately 1min/50mL, or until completely melted), and allow to cool 
for a few minutes.  While students are making their way into class, elect a volunteer to 
pour the gel and insert the comb to create wells.  
 
 Initiate class with: ‘While you weren’t looking, I ran a PCR with the primers you 
helped select in the last class. Now, we need to verify that the reaction worked, and we 
need to separate our product from the rest of the components of the PCR reaction.’  This 
is a good time to get the students to remind each other what the components of a PCR 
reaction are.  Ask the students how they propose to separate these components (the 
student(s) who helped to pour the gel should have some idea). 
 Introduce the concept of electrophoresis.  Draw a model gel on the board, with a 
band representing the PCR product, and a second band representing the primers, and ask 
which band is which. Students should be able to reason that the smaller molecules will 
travel faster.  [Students will be running the PCR reaction on the gel, however, they will 
not see the DNA until after the gel is stained with an appropriate staining solution. To 
avoid using potentially hazardous chemicals, our class did not stain the DNA in the gel, 
but they were shown a picture of their PCR product run on a gel stained with ethidium 
bromide.] 
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 By this point, the gel(s) should be solidified.  If this is the student’s first 
experience with using micropipettes, the general mechanism of the pipette should be 
described.  Additionally, using the micropipettes is a good opportunity to get the students 
to relate 1uL to 1L (how many mL in a L, how many uL in a ml, how many uL in a L?). 
Each student should have an opportunity to pipette some dye with the micropipette, even 
if there are not enough lanes in the gel(s) for everyone to pipette into the gel. 
 Students should be divided into groups, and while one group is learning to pipette 
and loading the gel, the other groups should be working on the ‘Cloning a Protein of 
Interest: Part II’ hand-out on electrophoresis.  The packet includes the size (MW) of the 
four dyes that students will be running on the gel, as well as the chemical structure, from 
which they may be able to determine the charge on the molecule.  Students are asked to 
predict how far and in which direction each of the dyes will run. 
 The gel should be run for approximately 20 minutes in order to separate the dyes.  
Once the gel is finished running, the students should compare their expected results to the 
observed results and come-up with possible explanations for any differences. 
Additionally, based on the results, the students should be able to determine what dyes 
were included in each of the ‘unknown’ mixtures.  
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Day 3. Cloning a protein of interest, Part III: Model ligation reaction 
(45 minute class) 
 
 Begin the class with an image of a restriction endonuclease, or restriction enzyme, 
attached to its recognition sequence within a strand of DNA.  Describe what happens to 
the DNA when the restriction enzyme recognizes a specific sequence of DNA.  Ask the 
students why an organism would develop such an enzyme – what purpose could it serve? 
Continue to explain that scientists now utilize these enzymes to cut DNA in specific 
patterns in order to assemble new DNA sequences. 
 Returning to that gene we copied with PCR and verified/cleaned-up with gel 
electrophoresis – what would happen if we put that DNA into bacteria?  What would the 
bacteria do with it? [Hopefully, the students will surmise that it would get degraded.] 
How can we convince the bacteria to maintain our DNA?  What has to happen to the 
plasmid in order for it to be passed on to the next generation of cells? 
 At this point, the ‘Cloning a protein of interest: PartIII’ handout should be 
distributed.  Students should work in groups of at least four, with each student having the 
three parts of the plasmid to work with.  Students should find the restriction enzyme cut 
sites and cut the ‘DNA’ accordingly, yielding three pieces with overhanging ‘sticky 
ends.’  Students should try to arrange their pieces in as many ways as possible.  There is 
one preferred arrangement, but the students should discover that many other 
arrangements are possible, particularly when students combine their pieces to make larger 
plasmids.  However, only plasmids that contain the antibiotic resistance marker and the 
origin of replication will be maintained and replicated by bacteria.  And, only those 
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plasmids that have the protein of interest oriented in the correct direction in relation to the 
promoter region will be capable of expressing the protein. 
 
 
Day 4. Cloning a protein of interest, Part IV: The Art of Science 
(90 minute class) 
 
Preparation: LB agar plates containing the antibiotic for which the plasmid confers 
resistance (kanamycin, in the case of pET28), and the inducer for the plasmid, if not 
constitutively active (IPTG, in the case of pET28), should be prepared in advance [Pre-
poured sterile agar plates containing antibiotic can be purchased from Sigma-Aldrich].  
Overnight cultures, grown at 37°C, should be inoculated the night before the activity. The 
morning of the activity, the cells should be aliquoted into small epi-tubes, <100uL each. 
 
 This activity is designed as the culminating experience for the module. During the 
first half of the class, students will be given plates and small aliquots of the bacteria 
containing an expression vector harboring the protein(s) of interest.  Several different 
fluorescent proteins are available – in our class, we used five different proteins: GFP 
(green), CFP (cyan), mStrawberry (pink), mTangerine (orange), and mHoneydew (light 
green).   
Prior to students obtaining their aliquots of bacteria, SAFETY must be 
emphasized.  Although this bacteria is considered non-pathogenic, it should be treated 
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with caution.  Students should wear gloves when handling the bacteria, and the bench 
tops should be cleaned with 70% EtOH after use. 
Using a pipette tip as a ‘paint brush’, and the bacterial cultures as ‘paint’, students 
will draw images on the plates, an excellent opportunity for artistically inclined 
individuals to share their talents. The plates need to be incubated overnight at 30°C in 
order for the cells to grow. 
 
 
 Once the students have cleaned-up the lab area, they should be challenged to 
come up with more practical uses for genetic engineering and recombinant DNA 
technology through a class discussion.  Some possible examples include: therapeutic 
protein production (insulin is the most common example), making large quantities of a 
protein to study its function, and creating biosensors that turn on/off based on 
environmental factors.  At this point, it can also be emphasized that bacteria do not have 
the same machinery as eukaryotic cells, and that the processing of proteins in bacteria is 
Figure'6.2.'Example'of'student'‘bacto=art’.'Students,!working!with!several!bacterial!cultures!expressing!different!fluorescent!proteins!as!‘paint’!and!pipet!tips!as!‘brushes,’!created!a!variety!of!different!bacto@art!samples,!which!were!later!imaged!under!blue!light.!!#
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different – in other words, the same protein sequence made in bacteria versus mammalian 
cells, could have a completely different shape, and therefore different function.  One 
example of a protein that requires eukaryotic cell culture is erythropoietin, a protein 
commonly used to treat anemia.  When erythropoietin is made in bacteria, the protein 
product is 1000x less effective than the same amino acid sequence produced in a 
mammalian cell line – the primary reason for the difference, in this case, is the lack of 
specific types of glycosylation, the addition of sugar groups, to proteins in bacteria. 
 
Extension activity 
 As an extension to this project, a lesson can be provided regarding fluorescence. 
Fluorescence is the emission of light by a substance that has absorbed light, or other 
electromagnetic radiation, of a different wavelength.  Fluorescent proteins, therefore, 
don’t ‘glow in the dark’, but they absorb light and emit a different wavelength of light 
with less energy. 
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Safety 
 
The bacteria used for cloning and expressing protein is considered non-pathogenic, 
however it should be handled with care.  Glove should be worn at all times, and changed 
if soiled.  All surfaces should be cleaned with a 70% Ethanol (EtOH) solution. 
 
Students should always wash hands before leaving the laboratory . 
 
TAE – contains Tris Base, Acetic Acid and EDTA, all of which are skin irritants, thus 
gloves should be worn at all times. 
 
Agarose –skin irritant, flush with water 
xylene cyanol – skin irritant, flush with water 
orange g – skin irritant, flush with water 
methyl green – skin irritant, flush with water 
bromophenol blue – skin irritant, flush with water 
 
Waste Disposal Method - All chemical and biological waste disposal must be in 
accordance with current local, state, and federal regulations. 
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Assessment 
 
Students were given a pre-test and a post-test in order to measure their previous 
knowledge and assess the level of comprehension gained through the activities.  A short-
answer questionnaire and/or a multiple choice problem set can be used.  The post-test is 
the same test as the pre-test, in order to provide direct comparison for statistical analysis. 
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Curriculum 2: 
Where in the Middle School can we find the most bacteria? 
 
 
Introduction 
 
 This teaching module was designed in collaboration with Michelle Kornreich, a 
science teacher at Boynton Middle School in Ithaca, NY, for 6th grade students enrolled 
in General Science.  The New York State – Intermediate Level Science standards covered 
in this curriculum include: Std. 1. Analysis, inquiry and design, Std. 4.4. Continuity of 
life, Std. 4.6. Interdependence of life, Std. 4.7. Humans impact their environment. 
 The schedule time frame for this curriculum is three 35 minute class periods. 
 
Description 
The primary objective of this activity is to make students aware of the microbial 
life in their environment and to help them better understand our complex ecosystem.  
Students will develop and test a hypothesis to address the question, ‘where in the middle 
school can we find the most bacteria?’ 
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Objectives 
• Develop hypotheses and test by sampling the environment. 
 
• Collect qualitative and quantitative data. 
 
• Analyze the results and provide suggestions for improving the experiment. 
 
• Develop new hypotheses based on the initial experimental results. 
 
 
Materials 
1-2 petri dishes for each pair of students, LB agar, q-tips, water, parafilm®, permanent 
markers, index cards 
 
Science Content for the Teacher 
 
 Our environment is full of life that is smaller than the eye can see.  These 
microorganisms play an essential role in the viability of our ecosystem – not only in the 
world around us, but also on and within each us.  It is estimated that there are more than 
10x more bacterial cells on the human body than there are human cells, and with an 
estimate of 10 trillion human cells composing the average human body, that means there 
are approximately 100 trillion bacteria covering us!  But don’t worry, by weight, we are 
definitely mostly human – human cells are, on average, 10x larger than most bacteria, 
and the human body is composed of a significant amount extracellular matrixes, 
compounds produced by our cells that help to hold us together. 
 Every surface of the human body that is exposed to the environment is covered in 
bacteria.  The majority of the bacterial cells that cohabitate with the human body reside in 
the gut.  These gut microorganisms are necessary for our survival, providing us with 
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many essential vitamins, digesting complex carbohydrates to usable forms, destroying 
cancer-inducing compounds196, and much more. 
 The natural flora that exist on and within the human body act, in many cases, as a 
defense mechanism against potential disease-causing, aka pathogenic, bacteria. For 
example, Staphylococcus epidermidis, a natural member of the normal skin flora, 
produces an enzyme, serine protease Esp, which has been shown to inhibit the growth of 
the more significantly pathogenic Staphylococcus aureus197.  
 The world around us is also covered in bacteria.  Most locations, unless sterilized 
with a sanitizing agent like chlorine, have an entire bacterial ecosystem in place. 
Microorganisms inhabit even places where no one would think life could exist, like 
thermal vents.  The unique microorganisms that exist in thermal vents have provided 
scientists with enzymes that have significantly impacted genetic research – specifically, 
these organisms code for heat-tolerant DNA polymerases that can be used for replicating 
DNA in a test tube in the laboratory, in-vitro.  
 Scientists have studied many of the different microorganisms in the environment, 
and new organisms are being discovered regularly. A variety of tools for understanding 
and manipulating biological systems have been discovered and/or designed in bacteria.  
Bacteria can be manipulated to produce proteins for use in humans – the first example to 
come to market was human Insulin, made in Escherichia coli from recombinant DNA, 
and marketed by Eli Lily and company in starting 1982. Prior to production in bacteria, 
insulin was purified from pigs, and many people were allergic to the pig protein.  
 The purpose of this activity is to help students to gain a better understanding of 
the world around them.  Microorganisms play a major role in our everyday lives, even 
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though many of us don’t even realize they are there.  Many of the practices we undertake 
to maintain sterile environments and to help our body fight-off infection, such as 
antibiotics, are potentially harmful to the delicately balanced ecosystem that maintains us. 
 
 
 
 
 
 
  
 !x10-1 
~2 meters 
(2000 millimeters) 
~0.2 meters 
(200 millimeters) ~0.02 meters 
(20 millimeters) 
~2 millimeters 
(2000 micrometers) 
~0.2 millimeters 
(200 micrometers) 
~0.02 millimeters 
(20 micrometers) 
~2 micrometers 
(2000 nanometers) 
Figure'6.3.''Understanding'size.!Bacteria!are!small,!approximately!10x!smaller!than!an!animal!cell.!!This!series!of!images!is!designed!to!help!students!visualize!size!difference!in!orders!of!magnitude.!!Included!in!this!figure!are!approximate!metric!measurements,!providing!the!opportunity!to!introduce/re@emphasize!the!prefixes!used!to!describe!small!things!in!metric!units.!Public!stock!photos!used!here!for!educational!purposes.!!
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Preparation 
 
 LB agar plates can be obtained pre-poured and ready-to-go from Sigma (L5542).  
Be sure not to purchase plates containing antibiotics, as this will prevent the growth of a 
larger portion of the sampled bacteria. 
 Q-tips, cut in half while attempting to maintain sterility, should be prepared ahead 
of time.  In addition, aliquots of sterile water should be prepared for each team (tap water 
will suffice if sterile water is not available). 
 
Classroom Procedure 
 
Engage: A 4-minute video entitled ‘Understanding Microbial Life’ is used to initiate 
student interest in finding-out where in their school they can find the most bacteria.   
 
Explore: Students are broken-up into teams and asked to come-up with a hypothesis as to 
where they believe the most bacteria live in their school. Teams then go out and sample 
the locations they agree to test. After three days incubating at room temperature, the 
results are analyzed by both qualitatively and quantitatively observing the plates. 
 
Explain: The results from all of the classes are compiled and presented to each class. The 
specifics of this presentation depend somewhat on the results, and results from multiple 
classes can be compiled.  
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Expand: Based on the observed results, students are challenged to come-up with new 
hypotheses and improved methods to address the question.   
 
Day 1: Opening day –  
Students watch a 4-minute video entitled ‘Understanding Microbial Life’. 
Students are then broken-up into teams and asked to come-up with and agree 
upon a hypothesis about where in their school they think they will find the most 
bacteria. 
 
Following an initial period of discussion among groups, the students are given a 
demonstration on how to sample a location.  A q-tip is dipped in water, wiped 
across the surface being sampled, and then streaked across the plate from left to 
right, down the length of the plate. Be certain to emphasize that the gelatin-like 
substance (LB agar) is what the bacteria feed on in order to grow (ie. If they 
streak their bacteria sample on the lid instead of on the agar, they will not find any 
bacteria after the plate is appropriately incubated.) 
 
All plates should be labeled along the edge with the group name and sample 
location – labeling the plates on the lid or on the bottom will make it difficult to 
collect data. 
 
Plates can be incubated for ~3 days at room temperature, or 1-2 days at warmer 
temperatures.  Incubation temperature should not exceed body temperature, 37°C. 
! 120!
 
Longer incubation times will lead to more fungal/mold growth.  Bacteria and 
fungus can be distinguished by their morphology – bacteria generally form round 
colonies, while fungus and mold have a variety of interesting morphologies.  In 
some cases, the fungus on a plate can inhibit bacterial growth around it.  This is 
how penicillin, the first antibiotic used to treat bacterial infections in humans, was 
discovered. 
 
Day 2: Data collection day – 
The plates are sealed with parafilm® before the students handle them in order to 
prevent aerosol of bacteria or fungal spores during the data collection. 
 
Qualitative data collection: The plates from each team are displayed along the 
outer edge of the class, with a corresponding number written on an index card.  
Each student has a chance to observe each plate.  Based on their observations, 
students decide up the three plates they believe have the most bacteria, taking into 
consideration both in variety and number.   
  
 
Quantitative data collection: Following the qualitative observations, each group 
takes their plate(s) back to their workspace to count colonies. Some plates will 
have a significant number of colonies, and students will have to devise methods to 
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count - one possibility is to divide the plate into approximately equal sections and 
count only one of those section, then multiplying by the total number of sections. 
 
Following the data collection, students should report their data.  This can be done 
directly into a computer program, such as excel, or written on a collection sheet.  
Students should also record their data in their journal. 
 
The teacher should compile the data from all of the classes in order to have 
meaningful results to report to the classes for Day 3.  If computers are available to 
the students, an extra day of the activity can be implemented, where students play 
with the raw data, create graphs and try to come to meaningful conclusions.   
 
Day 3: Closing day –  
Students are given a ‘pop quiz’ at the beginning of class to help assess their 
understanding of what we have discussed and explored over the course of this 
activity.  The questions in the hand-out correspond to topics covered in the video 
they watched on ‘Day 1’.  Students are given the opportunity to watch the video a 
second time as they fill-out the answers on their ‘pop quiz’.  
 
Students are asked to explain why we are able see the bacteria (because they 
multiplied and there are millions).  Students are also challenged to come-up with 
explanations for strange results.  For example, if the plates are incubated at room 
temperature, and one student samples bacteria from their body, the colonies will 
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be significantly smaller than those from bacteria sampled from a location that is 
normally at room temperature. 
 
The number of trials will be a limiting factor in good data analysis, and the 
students should come to this conclusion.  In some cases, interesting data will 
emerge.  In our class, we found that the peanut-free cafeteria table had 
significantly less bacteria than on of the regular tables, but only two data points, it 
is difficult to be certain of this difference. 
 
One question that should be asked is whether of not they cultured all of the 
bacteria in their location.  The answer is no, as only some bacteria can rapidly 
divide at the temperature and on the feed stocks used in this experiment.   
 
 
 
Extension Activities 
 
Following the initial data collection, many students will likely have more questions.  As 
an extension to this activity, students can design a new set of experiments to test their 
new hypotheses.  Alterations to the experiment can include testing different growth 
conditions, altering the food source for the bacteria or changing the temperature and/or 
duration of growth. 
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Safety 
 
Following growth of the microorganisms on the LB agar plates, the plates should be 
sealed with parafilm to avoid any bacterial or fungal spores from becoming air-born. The 
petri dishes with LB agar should not contain any significant pathogens and can be 
disposed of in the regular trash after being sealed with parafilm 
 
Waste Disposal Method - All chemical and biological waste disposal must be in 
accordance with current local, state, and federal regulations. 
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Conclusions 
 The passion that brought graduate students to their chosen field of study is often 
forgotten in the pressure and hectic pace of experimentation, scientific papers, and 
graduate course work. While there were several challenges associated with participation 
as a fellow in the Cornell’s Learning Initiative in Medicine and Bioengineering GK-12 
(CLIMB) program, including curriculum preparation and at least 10 hours each week 
dedicate to CLIMB classroom activities outside of the university laboratory, sharing 
science with middle school and high school teachers and students was a valuable 
experience. The CLIMB program reacquainted and reconnected me with my own passion 
for science while igniting an appetite and excitement in encouraging future scientists.  
 There was an interesting synergy between me and the partner teachers as we were 
all both student and teacher. My partner teachers, Ron Reed and Michelle Kornreich, are 
exceptional educators. I was fortunate to observe each educator in their environment and 
watch as they empowered their students using their own unique teaching skill set.  They 
both taught me techniques on how to translate complicated scientific concepts for the 
young middle school/high school minds. Since neither teacher had any prior experience 
with microbiology or molecular biology techniques, laboratory procedure proved a 
challenge. A significant amount of time was required to acclimate them to general 
laboratory procedures, but they were eager students. The knowledge exchange was a 
remarkable experience for each of us.   
 Students in both the 9th grade and 6th grade classrooms were excited to have their 
‘visiting scientist’ teach them about cutting-edge scientific progress.  In both the 9th grade 
and 6th grade classrooms, there was a notable change in attitude towards Science. Several 
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of the students in the 9th grade classroom requested the scientific papers that I addressed 
in some of the lectures, and a number of the 6th grade students expressed interest in 
perusing careers in science. 
 Participation as a fellow in this program has inspired me.  While it is not my 
desire to run and manage a middle school or secondary classroom, I look forward finding 
future opportunities to be a visiting scientist to help inspire more young people to take a 
serious interest in scientific research. 
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